Ignite Creation Date:
2025-12-24 @ 9:07 PM
Ignite Modification Date:
2025-12-25 @ 6:58 PM
Study NCT ID:
NCT04667104
Status:
COMPLETED
Last Update Posted:
2024-07-03
First Post:
2020-12-09
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'submissionTracking': {'firstMcpInfo': {'postDateStruct': {'date': '2024-05-14', 'type': 'ACTUAL'}}}}, 'conditionBrowseModule': {'meshes': [{'id': 'D019694', 'term': 'Hepatitis B, Chronic'}], 'ancestors': [{'id': 'D006509', 'term': 'Hepatitis B'}, {'id': 'D000086982', 'term': 'Blood-Borne Infections'}, {'id': 'D003141', 'term': 'Communicable Diseases'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D018347', 'term': 'Hepadnaviridae Infections'}, {'id': 'D004266', 'term': 'DNA Virus Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D006525', 'term': 'Hepatitis, Viral, Human'}, {'id': 'D006521', 'term': 'Hepatitis, Chronic'}, {'id': 'D006505', 'term': 'Hepatitis'}, {'id': 'D008107', 'term': 'Liver Diseases'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D002908', 'term': 'Chronic Disease'}, {'id': 'D020969', 'term': 'Disease Attributes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000068698', 'term': 'Tenofovir'}, {'id': 'C442442', 'term': 'tenofovir alafenamide'}, {'id': 'C413685', 'term': 'entecavir'}], 'ancestors': [{'id': 'D063065', 'term': 'Organophosphonates'}, {'id': 'D009943', 'term': 'Organophosphorus Compounds'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D000225', 'term': 'Adenine'}, {'id': 'D011687', 'term': 'Purines'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'ClinicalTrialDisclosure@its.jnj.com', 'phone': '844-434-4210', 'title': 'Clinical Registry Group', 'organization': 'Janssen Research & Development, LLC'}, 'certainAgreement': {'otherDetails': 'If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'Safety analysis set included all participants who received at least 1 dose of study intervention. Participants were analyzed according to the study intervention they actually received.', 'eventGroups': [{'id': 'EG000', 'title': 'TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA', 'description': 'Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir\\[ETV\\] 0.5 mg, tenofovir disoproxil fumarate\\[TDF\\] 245 mg, or tenofovir alafenamide\\[TAF\\] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2.', 'otherNumAtRisk': 48, 'deathsNumAtRisk': 48, 'otherNumAffected': 12, 'seriousNumAtRisk': 48, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA', 'description': 'Participants who met the eligibility criteria for PegIFN-alpha2a (Participants who did not have disorders including but not limited to: autoimmune disorders, bone marrow suppression, hypoglycemia, hyperglycemia, diabetes mellitus) at Week 12 received combination treatment with JNJ-73763989 200 mg SC injection Q4W along with NA treatment (either ETV 0.5 mg, TDF 245 mg, or TAF 25 mg) QD up to Week 24 plus PegIFN-alpha 2a 180 micrograms (mcg) once weekly (QIW) during TP 2. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after Protocol Amendment 3, received JNJ-73763989 + PegIFN alpha 2a + NA only.', 'otherNumAtRisk': 48, 'deathsNumAtRisk': 48, 'otherNumAffected': 35, 'seriousNumAtRisk': 48, 'deathsNumAffected': 0, 'seriousNumAffected': 1}, {'id': 'EG002', 'title': 'Follow-Up (FU) Period-nucleos(t)Ide Analog (NA)', 'description': 'At Week 24, prior to follow-up period, all participants stopped treatment with JNJ-73763989 + JNJ-56136379 + PegIFN-alpha2a. Participants who met the protocol-defined NA treatment completion criteria (hepatitis B surface antigen \\[HBsAg\\] \\<10 international units/millilitre \\[IU/mL\\], and hepatitis B e antigen \\[HBeAg\\]-negative, and hepatitis B virus deoxyribonucleic acid \\[HBV DNA\\] \\<20 IU/mL \\<lower limit of quantification \\[LLOQ\\], and alanine aminotransferase \\[ALT\\] \\<3\\*Upper limit of normal \\[ULN\\]) at Week 24, stopped NA at Week 26 (that is follow up Week 2). Participants who did not meet NA completion criteria continued NA treatment during the follow-up period up to follow-up Week 48 (with window period of +/- 4 days that is up to Week 72.4).', 'otherNumAtRisk': 48, 'deathsNumAtRisk': 48, 'otherNumAffected': 20, 'seriousNumAtRisk': 48, 'deathsNumAffected': 0, 'seriousNumAffected': 4}], 'otherEvents': [{'term': 'Leukopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 48, 'numEvents': 4, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.1'}, {'term': 'Neutropenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 48, 'numEvents': 6, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.1'}, {'term': 'Thrombocytopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 48, 'numEvents': 5, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 48, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.1'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 48, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.1'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 48, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 48, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 48, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.1'}, {'term': 'Influenza Like Illness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 48, 'numEvents': 7, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.1'}, {'term': 'Injection Site Erythema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 48, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 48, 'numEvents': 10, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.1'}, {'term': 'Pyrexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 48, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 48, 'numEvents': 18, 'numAffected': 15}, {'groupId': 'EG002', 'numAtRisk': 48, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.1'}, {'term': 'Covid-19', 'stats': [{'groupId': 'EG000', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 48, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 48, 'numEvents': 13, 'numAffected': 13}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.1'}, {'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 48, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 48, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 48, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.1'}, {'term': 'Upper Respiratory Tract Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 48, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 48, 'numEvents': 7, 'numAffected': 3}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.1'}, {'term': 'Alanine Aminotransferase Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 48, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 48, 'numEvents': 4, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.1'}, {'term': 'Neutrophil Count Decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 48, 'numEvents': 7, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.1'}, {'term': 'Decreased Appetite', 'stats': [{'groupId': 'EG000', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 48, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.1'}, {'term': 'Arthralgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 48, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.1'}, {'term': 'Myalgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 48, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 48, 'numEvents': 9, 'numAffected': 9}, {'groupId': 'EG002', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.1'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 48, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 48, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.1'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 48, 'numEvents': 4, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 48, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 48, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.1'}], 'seriousEvents': [{'term': 'Cholelithiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 48, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.1'}, {'term': 'Hepatic Mass', 'stats': [{'groupId': 'EG000', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 48, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.1'}, {'term': 'Urinary Tract Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 48, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.1'}, {'term': 'Gastric Cancer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 48, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.1'}, {'term': 'Hydronephrosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 48, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.1'}, {'term': 'Nephrolithiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 48, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.1'}, {'term': 'Ureterolithiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 48, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.1'}, {'term': 'Prostatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 48, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 25.1'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Percentage of Participants With a Reduction of at Least 2 log10 International Unit/Millilitres (IU/mL) in Hepatitis B Surface Antigen (HBsAg) Levels From Baseline to Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA', 'description': 'Participants who met the eligibility criteria for PegIFN-alpha2a (Participants who did not have disorders including but not limited to: autoimmune disorders, bone marrow suppression, hypoglycemia, hyperglycemia, diabetes mellitus) at Week 12 received combination treatment with JNJ-73763989 200 mg SC injection Q4W along with NA treatment (either ETV 0.5 mg, TDF 245 mg, or TAF 25 mg) QD up to Week 24 plus PegIFN-alpha 2a 180 micrograms (mcg) once weekly (QIW) during TP 2. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after Protocol Amendment 3, received JNJ-73763989 + PegIFN alpha 2a + NA only.'}], 'classes': [{'categories': [{'measurements': [{'value': '64.6', 'spread': '51.73', 'groupId': 'OG000', 'lowerLimit': '51.73', 'upperLimit': '76.02'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From Baseline (Day 1) to Week 24', 'description': 'Percentage of participants with a reduction of at least 2 log10IU/mL in HBsAg levels from baseline to Week 24 were reported. A responder was defined as a participant with reduction of at least 2 log10 IU/mL in HBsAg levels from baseline at Week 24.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '90% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set (FAS) included all participants who were enrolled and who received at least 1 dose of study intervention within this intervention-specific appendix (ISA). Data for this outcome measure was planned to be collected and analyzed for specified arm only.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) as a Measure of Safety and Tolerability', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '48', 'groupId': 'OG001'}, {'value': '48', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA', 'description': 'Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir\\[ETV\\] 0.5 mg, tenofovir disoproxil fumarate\\[TDF\\] 245 mg, or tenofovir alafenamide\\[TAF\\] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2.'}, {'id': 'OG001', 'title': 'TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA', 'description': 'Participants who met the eligibility criteria for PegIFN-alpha2a (Participants who did not have disorders including but not limited to: autoimmune disorders, bone marrow suppression, hypoglycemia, hyperglycemia, diabetes mellitus) at Week 12 received combination treatment with JNJ-73763989 200 mg SC injection Q4W along with NA treatment (either ETV 0.5 mg, TDF 245 mg, or TAF 25 mg) QD up to Week 24 plus PegIFN-alpha 2a 180 micrograms (mcg) once weekly (QIW) during TP 2. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after Protocol Amendment 3, received JNJ-73763989 + PegIFN alpha 2a + NA only.'}, {'id': 'OG002', 'title': 'Follow-Up (FU) Period-nucleos(t)Ide Analog (NA)', 'description': 'At Week 24, prior to follow-up period, all participants stopped treatment with JNJ-73763989 + JNJ-56136379 + PegIFN-alpha2a. Participants who met the protocol-defined NA treatment completion criteria (hepatitis B surface antigen \\[HBsAg\\] \\<10 international units/millilitre \\[IU/mL\\], and hepatitis B e antigen \\[HBeAg\\]-negative, and hepatitis B virus deoxyribonucleic acid \\[HBV DNA\\] \\<20 IU/mL \\<lower limit of quantification \\[LLOQ\\], and alanine aminotransferase \\[ALT\\] \\<3\\*Upper limit of normal \\[ULN\\]) at Week 24, stopped NA at Week 26 (that is follow up Week 2). Participants who did not meet NA completion criteria continued NA treatment during the follow-up period up to follow-up Week 48 (with window period of +/- 4 days that is up to Week 72.4).'}], 'classes': [{'categories': [{'measurements': [{'value': '52.1', 'groupId': 'OG000'}, {'value': '87.5', 'groupId': 'OG001'}, {'value': '60.4', 'groupId': 'OG002'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up Period: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'Percentage of participants with TEAEs were reported. An adverse event (AE) was any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs were AEs with onset during the intervention period or follow-up period or that were a consequence of a pre-existing condition that had worsened since baseline.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants who received at least 1 dose of study intervention. Participants were analyzed according to the study intervention they actually received.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '48', 'groupId': 'OG001'}, {'value': '48', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA', 'description': 'Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir\\[ETV\\] 0.5 mg, tenofovir disoproxil fumarate\\[TDF\\] 245 mg, or tenofovir alafenamide\\[TAF\\] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2.'}, {'id': 'OG001', 'title': 'TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA', 'description': 'Participants who met the eligibility criteria for PegIFN-alpha2a (Participants who did not have disorders including but not limited to: autoimmune disorders, bone marrow suppression, hypoglycemia, hyperglycemia, diabetes mellitus) at Week 12 received combination treatment with JNJ-73763989 200 mg SC injection Q4W along with NA treatment (either ETV 0.5 mg, TDF 245 mg, or TAF 25 mg) QD up to Week 24 plus PegIFN-alpha 2a 180 micrograms (mcg) once weekly (QIW) during TP 2. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after Protocol Amendment 3, received JNJ-73763989 + PegIFN alpha 2a + NA only.'}, {'id': 'OG002', 'title': 'Follow-Up (FU) Period-nucleos(t)Ide Analog (NA)', 'description': 'At Week 24, prior to follow-up period, all participants stopped treatment with JNJ-73763989 + JNJ-56136379 + PegIFN-alpha2a. Participants who met the protocol-defined NA treatment completion criteria (hepatitis B surface antigen \\[HBsAg\\] \\<10 international units/millilitre \\[IU/mL\\], and hepatitis B e antigen \\[HBeAg\\]-negative, and hepatitis B virus deoxyribonucleic acid \\[HBV DNA\\] \\<20 IU/mL \\<lower limit of quantification \\[LLOQ\\], and alanine aminotransferase \\[ALT\\] \\<3\\*Upper limit of normal \\[ULN\\]) at Week 24, stopped NA at Week 26 (that is follow up Week 2). Participants who did not meet NA completion criteria continued NA treatment during the follow-up period up to follow-up Week 48 (with window period of +/- 4 days that is up to Week 72.4).'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '2.1', 'groupId': 'OG001'}, {'value': '8.3', 'groupId': 'OG002'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up Period: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs were AEs with onset during the intervention period or follow-up period or that were a consequence of a pre-existing condition that had worsened since baseline. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants who received at least 1 dose of study intervention. Participants were analyzed according to the study intervention they actually received.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Clinically Significant Abnormalities in Vital Signs as a Measure of Safety and Tolerability', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '48', 'groupId': 'OG001'}, {'value': '48', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA', 'description': 'Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir\\[ETV\\] 0.5 mg, tenofovir disoproxil fumarate\\[TDF\\] 245 mg, or tenofovir alafenamide\\[TAF\\] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2.'}, {'id': 'OG001', 'title': 'TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA', 'description': 'Participants who met the eligibility criteria for PegIFN-alpha2a (Participants who did not have disorders including but not limited to: autoimmune disorders, bone marrow suppression, hypoglycemia, hyperglycemia, diabetes mellitus) at Week 12 received combination treatment with JNJ-73763989 200 mg SC injection Q4W along with NA treatment (either ETV 0.5 mg, TDF 245 mg, or TAF 25 mg) QD up to Week 24 plus PegIFN-alpha 2a 180 micrograms (mcg) once weekly (QIW) during TP 2. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after Protocol Amendment 3, received JNJ-73763989 + PegIFN alpha 2a + NA only.'}, {'id': 'OG002', 'title': 'Follow-Up (FU) Period-nucleos(t)Ide Analog (NA)', 'description': 'At Week 24, prior to follow-up period, all participants stopped treatment with JNJ-73763989 + JNJ-56136379 + PegIFN-alpha2a. Participants who met the protocol-defined NA treatment completion criteria (hepatitis B surface antigen \\[HBsAg\\] \\<10 international units/millilitre \\[IU/mL\\], and hepatitis B e antigen \\[HBeAg\\]-negative, and hepatitis B virus deoxyribonucleic acid \\[HBV DNA\\] \\<20 IU/mL \\<lower limit of quantification \\[LLOQ\\], and alanine aminotransferase \\[ALT\\] \\<3\\*Upper limit of normal \\[ULN\\]) at Week 24, stopped NA at Week 26 (that is follow up Week 2). Participants who did not meet NA completion criteria continued NA treatment during the follow-up period up to follow-up Week 48 (with window period of +/- 4 days that is up to Week 72.4).'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up Period: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'Number of participants with clinically significant abnormalities in vital signs (pulse rate, and blood pressure \\[systolic and diastolic\\]) were reported.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants who received at least 1 dose of study intervention. Participants were analyzed according to the study intervention they actually received.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Clinically Significant Abnormalities in Laboratory Findings as a Measure of Safety and Tolerability', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '48', 'groupId': 'OG001'}, {'value': '48', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA', 'description': 'Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir\\[ETV\\] 0.5 mg, tenofovir disoproxil fumarate\\[TDF\\] 245 mg, or tenofovir alafenamide\\[TAF\\] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2.'}, {'id': 'OG001', 'title': 'TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA', 'description': 'Participants who met the eligibility criteria for PegIFN-alpha2a (Participants who did not have disorders including but not limited to: autoimmune disorders, bone marrow suppression, hypoglycemia, hyperglycemia, diabetes mellitus) at Week 12 received combination treatment with JNJ-73763989 200 mg SC injection Q4W along with NA treatment (either ETV 0.5 mg, TDF 245 mg, or TAF 25 mg) QD up to Week 24 plus PegIFN-alpha 2a 180 micrograms (mcg) once weekly (QIW) during TP 2. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after Protocol Amendment 3, received JNJ-73763989 + PegIFN alpha 2a + NA only.'}, {'id': 'OG002', 'title': 'Follow-Up (FU) Period-nucleos(t)Ide Analog (NA)', 'description': 'At Week 24, prior to follow-up period, all participants stopped treatment with JNJ-73763989 + JNJ-56136379 + PegIFN-alpha2a. Participants who met the protocol-defined NA treatment completion criteria (hepatitis B surface antigen \\[HBsAg\\] \\<10 international units/millilitre \\[IU/mL\\], and hepatitis B e antigen \\[HBeAg\\]-negative, and hepatitis B virus deoxyribonucleic acid \\[HBV DNA\\] \\<20 IU/mL \\<lower limit of quantification \\[LLOQ\\], and alanine aminotransferase \\[ALT\\] \\<3\\*Upper limit of normal \\[ULN\\]) at Week 24, stopped NA at Week 26 (that is follow up Week 2). Participants who did not meet NA completion criteria continued NA treatment during the follow-up period up to follow-up Week 48 (with window period of +/- 4 days that is up to Week 72.4).'}], 'classes': [{'title': 'Treatment-emergent (TE)-Grade 3 ALT elevations', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}, {'title': 'TE-Grade 3 total bilirubin elevations', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}, {'title': 'TE-Grade 3 direct bilirubin elevations', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}]}]}, {'title': 'Treatment-emergent-High serum indirect bilirubin', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}]}]}, {'title': 'Renal complications-eGFR Decreases', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Hematology-low absolute neutrophil count Grade 1', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}]}]}, {'title': 'Hematology-low absolute neutrophil count Grade 2', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}, {'title': 'Hematology-low absolute neutrophil count Grade 3', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Hematology-low absolute neutrophil count Grade 4', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Hematology-low absolute lymphocyte count Grade 1', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Hematology-low absolute lymphocyte count Grade 2', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Hematology-low absolute lymphocyte count Grade 3', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}]}]}, {'title': 'Hematology-low absolute lymphocyte count Grade 4', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}, {'title': 'Hematology-decreased platelets of Grade 1', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}]}]}, {'title': 'Hematology-decreased platelets of Grade 2', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Hematology-low hemoglobin Grade 2', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}, {'title': 'Hematology-low WBC count of Grade 1', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}]}]}, {'title': 'Hematology-low WBC count of Grade 2', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}, {'title': 'Hematology-low WBC count of Grade 3', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Chemistry-LDL cholesterol Grade 3', 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}]}]}, {'title': 'Chemistry-eGFR creatinine low Grade 3 elevation', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Chemistry-eGFR Cystatin C low Grade 3 elevation', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}]}]}, {'title': 'Chemistry-Grade 3 elevations in triglycerides', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Chemistry-Grade 3 elevation amylase', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}, {'title': 'Chemistry-Grade 3 elevation direct bilirubin high', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}]}]}, {'title': 'Chemistry-lipaseGrade 4 elevation', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}, {'title': 'Urinalysis-Grade 1 glycosuria', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}, {'title': 'Urinalysis-Grade 1 hematuria', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}, {'title': 'Urinalysis-Grade 2 hematuria', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}, {'title': 'Urinalysis-Grade 1 proteinuria', 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}]}]}, {'title': 'Urinalysis-Grade 2 proteinuria', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up Period: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'Number of participants with clinically significant abnormalities in laboratory findings (including hematology, blood biochemistry, and urinalysis) were reported. Only parameters in which any participant had abnormality are reported below.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants who received at least 1 dose of study intervention. Participants were analyzed according to the study intervention they actually received. Here "N" (Number of participants analyzed) signifies the number of participants that were evaluable for this endpoint and "n"(number analyzed) signifies number of participants analyzed at specified timepoints.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECGs) as a Measure of Safety and Tolerability', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '48', 'groupId': 'OG001'}, {'value': '48', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA', 'description': 'Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir\\[ETV\\] 0.5 mg, tenofovir disoproxil fumarate\\[TDF\\] 245 mg, or tenofovir alafenamide\\[TAF\\] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2.'}, {'id': 'OG001', 'title': 'TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA', 'description': 'Participants who met the eligibility criteria for PegIFN-alpha2a (Participants who did not have disorders including but not limited to: autoimmune disorders, bone marrow suppression, hypoglycemia, hyperglycemia, diabetes mellitus) at Week 12 received combination treatment with JNJ-73763989 200 mg SC injection Q4W along with NA treatment (either ETV 0.5 mg, TDF 245 mg, or TAF 25 mg) QD up to Week 24 plus PegIFN-alpha 2a 180 micrograms (mcg) once weekly (QIW) during TP 2. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after Protocol Amendment 3, received JNJ-73763989 + PegIFN alpha 2a + NA only.'}, {'id': 'OG002', 'title': 'Follow-Up (FU) Period-nucleos(t)Ide Analog (NA)', 'description': 'At Week 24, prior to follow-up period, all participants stopped treatment with JNJ-73763989 + JNJ-56136379 + PegIFN-alpha2a. Participants who met the protocol-defined NA treatment completion criteria (hepatitis B surface antigen \\[HBsAg\\] \\<10 international units/millilitre \\[IU/mL\\], and hepatitis B e antigen \\[HBeAg\\]-negative, and hepatitis B virus deoxyribonucleic acid \\[HBV DNA\\] \\<20 IU/mL \\<lower limit of quantification \\[LLOQ\\], and alanine aminotransferase \\[ALT\\] \\<3\\*Upper limit of normal \\[ULN\\]) at Week 24, stopped NA at Week 26 (that is follow up Week 2). Participants who did not meet NA completion criteria continued NA treatment during the follow-up period up to follow-up Week 48 (with window period of +/- 4 days that is up to Week 72.4).'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up Period: From Week 24 up to Week 28', 'description': 'Number of participants with clinically significant abnormalities in 12- lead ECGs (heart rate, PR, QRS and QT corrected \\[QTc\\]) were reported.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants who received at least 1 dose of study intervention. Participants were analyzed according to the study intervention they actually received.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Clinically Significant Abnormalities in Physical Examination as a Measure of Safety and Tolerability', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '48', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA', 'description': 'Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir\\[ETV\\] 0.5 mg, tenofovir disoproxil fumarate\\[TDF\\] 245 mg, or tenofovir alafenamide\\[TAF\\] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2.'}, {'id': 'OG001', 'title': 'TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA', 'description': 'Participants who met the eligibility criteria for PegIFN-alpha2a (Participants who did not have disorders including but not limited to: autoimmune disorders, bone marrow suppression, hypoglycemia, hyperglycemia, diabetes mellitus) at Week 12 received combination treatment with JNJ-73763989 200 mg SC injection Q4W along with NA treatment (either ETV 0.5 mg, TDF 245 mg, or TAF 25 mg) QD up to Week 24 plus PegIFN-alpha 2a 180 micrograms (mcg) once weekly (QIW) during TP 2. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after Protocol Amendment 3, received JNJ-73763989 + PegIFN alpha 2a + NA only.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24', 'description': 'Number of participants with clinically significant abnormalities in physical examination were reported.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants who received at least 1 dose of study intervention. Participants were analyzed according to the study intervention they actually received. Data for this outcome measure was not planned to be collected and analyzed for Follow-Up Period as pre-specified in protocol.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Abnormalities in Ophthalmic Examination as a Measure of Safety and Tolerability', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA', 'description': 'Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir\\[ETV\\] 0.5 mg, tenofovir disoproxil fumarate\\[TDF\\] 245 mg, or tenofovir alafenamide\\[TAF\\] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2.'}, {'id': 'OG001', 'title': 'TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA', 'description': 'Participants who met the eligibility criteria for PegIFN-alpha2a (Participants who did not have disorders including but not limited to: autoimmune disorders, bone marrow suppression, hypoglycemia, hyperglycemia, diabetes mellitus) at Week 12 received combination treatment with JNJ-73763989 200 mg SC injection Q4W along with NA treatment (either ETV 0.5 mg, TDF 245 mg, or TAF 25 mg) QD up to Week 24 plus PegIFN-alpha 2a 180 micrograms (mcg) once weekly (QIW) during TP 2. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after Protocol Amendment 3, received JNJ-73763989 + PegIFN alpha 2a + NA only.'}], 'timeFrame': 'Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24', 'description': 'Number of participants with abnormalities in Ophthalmic examination were planned to be reported.', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants who received at least 1 dose of study intervention. Participants were analyzed according to the study intervention they actually received. Data for this outcome measure was planned to be collected and analyzed at TP 1 and TP 2 for participants with diabetes/hypertension only. Since no subject had diabetes/hypertension hence data for this OM was not collected and analyzed as pre-specified in protocol.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Meeting the Protocol-defined Nucleos(t)Ide Analog (NA) Treatment Completion Criteria at End of Study Intervention (EOSI)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA', 'description': 'Participants who met the eligibility criteria for PegIFN-alpha2a (Participants who did not have disorders including but not limited to: autoimmune disorders, bone marrow suppression, hypoglycemia, hyperglycemia, diabetes mellitus) at Week 12 received combination treatment with JNJ-73763989 200 mg SC injection Q4W along with NA treatment (either ETV 0.5 mg, TDF 245 mg, or TAF 25 mg) QD up to Week 24 plus PegIFN-alpha 2a 180 micrograms (mcg) once weekly (QIW) during TP 2. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after Protocol Amendment 3, received JNJ-73763989 + PegIFN alpha 2a + NA only.'}], 'classes': [{'categories': [{'measurements': [{'value': '31.3', 'groupId': 'OG000'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'At Week 24 (EOSI)', 'description': 'Percentage of participants meeting the protocol-defined NA treatment completion criteria at EOSI were reported. NA treatment completion criteria are defined based on laboratory results at Week 24 were; HBsAg \\<10 IU/mL; HBeAg-negative; HBV DNA \\<20 IU/mL, that is, lower limit of quantification(LLOQ); alanine aminotransferase(ALT) \\<3\\*ULN.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all participants who were enrolled and who received at least 1 dose of study intervention within this ISA. Data for this outcome measure was not planned to be collected and analyzed for Treatment Period 1 and Follow-Up period as pre-specified in protocol.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Hepatitis B e Antigen (HBeAg) Levels Below Different Cut-offs', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '11', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA', 'description': 'Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir\\[ETV\\] 0.5 mg, tenofovir disoproxil fumarate\\[TDF\\] 245 mg, or tenofovir alafenamide\\[TAF\\] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2.'}, {'id': 'OG001', 'title': 'TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA', 'description': 'Participants who met the eligibility criteria for PegIFN-alpha2a (Participants who did not have disorders including but not limited to: autoimmune disorders, bone marrow suppression, hypoglycemia, hyperglycemia, diabetes mellitus) at Week 12 received combination treatment with JNJ-73763989 200 mg SC injection Q4W along with NA treatment (either ETV 0.5 mg, TDF 245 mg, or TAF 25 mg) QD up to Week 24 plus PegIFN-alpha 2a 180 micrograms (mcg) once weekly (QIW) during TP 2. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after Protocol Amendment 3, received JNJ-73763989 + PegIFN alpha 2a + NA only.'}, {'id': 'OG002', 'title': 'Follow-Up (FU) Period-nucleos(t)Ide Analog (NA)', 'description': 'At Week 24, prior to follow-up period, all participants stopped treatment with JNJ-73763989 + JNJ-56136379 + PegIFN-alpha2a. Participants who met the protocol-defined NA treatment completion criteria (hepatitis B surface antigen \\[HBsAg\\] \\<10 international units/millilitre \\[IU/mL\\], and hepatitis B e antigen \\[HBeAg\\]-negative, and hepatitis B virus deoxyribonucleic acid \\[HBV DNA\\] \\<20 IU/mL \\<lower limit of quantification \\[LLOQ\\], and alanine aminotransferase \\[ALT\\] \\<3\\*Upper limit of normal \\[ULN\\]) at Week 24, stopped NA at Week 26 (that is follow up Week 2). Participants who did not meet NA completion criteria continued NA treatment during the follow-up period up to follow-up Week 48 (with window period of +/- 4 days that is up to Week 72.4).'}], 'classes': [{'title': '< LLOQ (0.11 IU/mL)', 'categories': [{'measurements': [{'value': '36.4', 'groupId': 'OG000'}, {'value': '27.3', 'groupId': 'OG001'}, {'value': '27.3', 'groupId': 'OG002'}]}]}, {'title': '< 1 IU/mL', 'categories': [{'measurements': [{'value': '90.9', 'groupId': 'OG000'}, {'value': '100.0', 'groupId': 'OG001'}, {'value': '81.8', 'groupId': 'OG002'}]}]}, {'title': '< 10 IU/mL', 'categories': [{'measurements': [{'value': '100.0', 'groupId': 'OG000'}, {'value': '100.0', 'groupId': 'OG001'}, {'value': '100.0', 'groupId': 'OG002'}]}]}, {'title': '< 100 IU/mL', 'categories': [{'measurements': [{'value': '100.0', 'groupId': 'OG000'}, {'value': '100.0', 'groupId': 'OG001'}, {'value': '100.0', 'groupId': 'OG002'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up Period: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'Percentage of participants with HBeAg levels below different cut-offs were reported. The cut-offs for HBeAg levels were as followed:\\< 100 IU/mL, \\< 10 IU/mL, \\< 1 IU/mL, \\< LLOQ (0.11 IU/mL).', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all participants who were enrolled and who received at least 1 dose of study intervention within this ISA. Here "N" (Number of participants analyzed) signifies the number of participants that were evaluable for this outcome measure.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With HBsAg Levels Below Different Cut-offs', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '48', 'groupId': 'OG001'}, {'value': '48', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA', 'description': 'Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir\\[ETV\\] 0.5 mg, tenofovir disoproxil fumarate\\[TDF\\] 245 mg, or tenofovir alafenamide\\[TAF\\] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2.'}, {'id': 'OG001', 'title': 'TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA', 'description': 'Participants who met the eligibility criteria for PegIFN-alpha2a (Participants who did not have disorders including but not limited to: autoimmune disorders, bone marrow suppression, hypoglycemia, hyperglycemia, diabetes mellitus) at Week 12 received combination treatment with JNJ-73763989 200 mg SC injection Q4W along with NA treatment (either ETV 0.5 mg, TDF 245 mg, or TAF 25 mg) QD up to Week 24 plus PegIFN-alpha 2a 180 micrograms (mcg) once weekly (QIW) during TP 2. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after Protocol Amendment 3, received JNJ-73763989 + PegIFN alpha 2a + NA only.'}, {'id': 'OG002', 'title': 'Follow-Up (FU) Period-nucleos(t)Ide Analog (NA)', 'description': 'At Week 24, prior to follow-up period, all participants stopped treatment with JNJ-73763989 + JNJ-56136379 + PegIFN-alpha2a. Participants who met the protocol-defined NA treatment completion criteria (hepatitis B surface antigen \\[HBsAg\\] \\<10 international units/millilitre \\[IU/mL\\], and hepatitis B e antigen \\[HBeAg\\]-negative, and hepatitis B virus deoxyribonucleic acid \\[HBV DNA\\] \\<20 IU/mL \\<lower limit of quantification \\[LLOQ\\], and alanine aminotransferase \\[ALT\\] \\<3\\*Upper limit of normal \\[ULN\\]) at Week 24, stopped NA at Week 26 (that is follow up Week 2). Participants who did not meet NA completion criteria continued NA treatment during the follow-up period up to follow-up Week 48 (with window period of +/- 4 days that is up to Week 72.4).'}], 'classes': [{'title': '<LLOQ (0.05 IU/mL)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '2.1', 'groupId': 'OG001'}, {'value': '2.1', 'groupId': 'OG002'}]}]}, {'title': '<1 IU/mL', 'categories': [{'measurements': [{'value': '4.2', 'groupId': 'OG000'}, {'value': '6.3', 'groupId': 'OG001'}, {'value': '2.1', 'groupId': 'OG002'}]}]}, {'title': '<10 IU/mL', 'categories': [{'measurements': [{'value': '12.5', 'groupId': 'OG000'}, {'value': '47.9', 'groupId': 'OG001'}, {'value': '4.2', 'groupId': 'OG002'}]}]}, {'title': '<100 IU/mL', 'categories': [{'measurements': [{'value': '58.3', 'groupId': 'OG000'}, {'value': '91.7', 'groupId': 'OG001'}, {'value': '27.1', 'groupId': 'OG002'}]}]}, {'title': '<1000 IU/mL', 'categories': [{'measurements': [{'value': '89.6', 'groupId': 'OG000'}, {'value': '97.9', 'groupId': 'OG001'}, {'value': '68.8', 'groupId': 'OG002'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up Period: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'Percentage of participants with HBsAg levels below different cut-offs were reported. The cut-offs for HBsAg level were: \\<1000 IU/mL, \\<100 IU/mL, \\<10 IU/mL, \\<1 IU/mL, \\<LLOQ (0.05 IU/mL).', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all participants who were enrolled and who received at least 1 dose of study intervention within this ISA.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels Below Different Cut-offs', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '48', 'groupId': 'OG001'}, {'value': '48', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA', 'description': 'Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir\\[ETV\\] 0.5 mg, tenofovir disoproxil fumarate\\[TDF\\] 245 mg, or tenofovir alafenamide\\[TAF\\] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2.'}, {'id': 'OG001', 'title': 'TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA', 'description': 'Participants who met the eligibility criteria for PegIFN-alpha2a (Participants who did not have disorders including but not limited to: autoimmune disorders, bone marrow suppression, hypoglycemia, hyperglycemia, diabetes mellitus) at Week 12 received combination treatment with JNJ-73763989 200 mg SC injection Q4W along with NA treatment (either ETV 0.5 mg, TDF 245 mg, or TAF 25 mg) QD up to Week 24 plus PegIFN-alpha 2a 180 micrograms (mcg) once weekly (QIW) during TP 2. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after Protocol Amendment 3, received JNJ-73763989 + PegIFN alpha 2a + NA only.'}, {'id': 'OG002', 'title': 'Follow-Up (FU) Period-nucleos(t)Ide Analog (NA)', 'description': 'At Week 24, prior to follow-up period, all participants stopped treatment with JNJ-73763989 + JNJ-56136379 + PegIFN-alpha2a. Participants who met the protocol-defined NA treatment completion criteria (hepatitis B surface antigen \\[HBsAg\\] \\<10 international units/millilitre \\[IU/mL\\], and hepatitis B e antigen \\[HBeAg\\]-negative, and hepatitis B virus deoxyribonucleic acid \\[HBV DNA\\] \\<20 IU/mL \\<lower limit of quantification \\[LLOQ\\], and alanine aminotransferase \\[ALT\\] \\<3\\*Upper limit of normal \\[ULN\\]) at Week 24, stopped NA at Week 26 (that is follow up Week 2). Participants who did not meet NA completion criteria continued NA treatment during the follow-up period up to follow-up Week 48 (with window period of +/- 4 days that is up to Week 72.4).'}], 'classes': [{'title': '< LLOQ for target detected and not detected', 'categories': [{'measurements': [{'value': '95.8', 'groupId': 'OG000'}, {'value': '75.0', 'groupId': 'OG001'}, {'value': '81.3', 'groupId': 'OG002'}]}]}, {'title': '< LLOQ for target not detected', 'categories': [{'measurements': [{'value': '52.1', 'groupId': 'OG000'}, {'value': '27.1', 'groupId': 'OG001'}, {'value': '54.2', 'groupId': 'OG002'}]}]}, {'title': '< LLOQ for target detected', 'categories': [{'measurements': [{'value': '43.8', 'groupId': 'OG000'}, {'value': '47.9', 'groupId': 'OG001'}, {'value': '27.1', 'groupId': 'OG002'}]}]}, {'title': '< 60 IU/mL', 'categories': [{'measurements': [{'value': '100.0', 'groupId': 'OG000'}, {'value': '89.6', 'groupId': 'OG001'}, {'value': '83.3', 'groupId': 'OG002'}]}]}, {'title': '< 100 IU/mL', 'categories': [{'measurements': [{'value': '100.0', 'groupId': 'OG000'}, {'value': '95.8', 'groupId': 'OG001'}, {'value': '83.3', 'groupId': 'OG002'}]}]}, {'title': '< 200 IU/mL', 'categories': [{'measurements': [{'value': '100.0', 'groupId': 'OG000'}, {'value': '97.9', 'groupId': 'OG001'}, {'value': '85.4', 'groupId': 'OG002'}]}]}, {'title': '< 1000 IU/mL', 'categories': [{'measurements': [{'value': '100.0', 'groupId': 'OG000'}, {'value': '100.0', 'groupId': 'OG001'}, {'value': '89.6', 'groupId': 'OG002'}]}]}, {'title': '< 2000 IU/mL', 'categories': [{'measurements': [{'value': '100.0', 'groupId': 'OG000'}, {'value': '100.0', 'groupId': 'OG001'}, {'value': '93.8', 'groupId': 'OG002'}]}]}, {'title': '< 20000 IU/mL', 'categories': [{'measurements': [{'value': '100.0', 'groupId': 'OG000'}, {'value': '100.0', 'groupId': 'OG001'}, {'value': '97.9', 'groupId': 'OG002'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up Period: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'Percentage of participants with HBV DNA levels below cut-offs were reported. The cut-offs for HBV DNA were as follows: \\<LLOQ (=20 IU/mL) target detected or not detected, \\< LLOQ target not detected, and \\< LLOQ target detected, \\<60 IU/mL, \\<100 IU/mL, \\<200 IU/mL, \\<1000 IU/mL, \\<2000 IU/mL, \\<20000 IU/mL.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all participants who were enrolled and who received at least 1 dose of study intervention within this ISA.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With ALT Levels Greater Than or Equal to (>=) 3*ULN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA', 'description': 'Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir\\[ETV\\] 0.5 mg, tenofovir disoproxil fumarate\\[TDF\\] 245 mg, or tenofovir alafenamide\\[TAF\\] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2.'}, {'id': 'OG001', 'title': 'TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA', 'description': 'Participants who met the eligibility criteria for PegIFN-alpha2a (Participants who did not have disorders including but not limited to: autoimmune disorders, bone marrow suppression, hypoglycemia, hyperglycemia, diabetes mellitus) at Week 12 received combination treatment with JNJ-73763989 200 mg SC injection Q4W along with NA treatment (either ETV 0.5 mg, TDF 245 mg, or TAF 25 mg) QD up to Week 24 plus PegIFN-alpha 2a 180 micrograms (mcg) once weekly (QIW) during TP 2. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after Protocol Amendment 3, received JNJ-73763989 + PegIFN alpha 2a + NA only.'}, {'id': 'OG002', 'title': 'Follow-Up (FU) Period-nucleos(t)Ide Analog (NA)', 'description': 'At Week 24, prior to follow-up period, all participants stopped treatment with JNJ-73763989 + JNJ-56136379 + PegIFN-alpha2a. Participants who met the protocol-defined NA treatment completion criteria (hepatitis B surface antigen \\[HBsAg\\] \\<10 international units/millilitre \\[IU/mL\\], and hepatitis B e antigen \\[HBeAg\\]-negative, and hepatitis B virus deoxyribonucleic acid \\[HBV DNA\\] \\<20 IU/mL \\<lower limit of quantification \\[LLOQ\\], and alanine aminotransferase \\[ALT\\] \\<3\\*Upper limit of normal \\[ULN\\]) at Week 24, stopped NA at Week 26 (that is follow up Week 2). Participants who did not meet NA completion criteria continued NA treatment during the follow-up period up to follow-up Week 48 (with window period of +/- 4 days that is up to Week 72.4).'}], 'classes': [{'categories': [{'measurements': [{'value': '33.3', 'groupId': 'OG000'}, {'value': '33.3', 'groupId': 'OG001'}, {'value': '66.7', 'groupId': 'OG002'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up Period: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'Percentage of participants with ALT levels below \\>=3\\*ULN cut-off were reported.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all participants who were enrolled and who received at least 1 dose of study intervention within this ISA. Here "N" (Number of participants analyzed) signifies the number of participants that were evaluable for this outcome measure.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With HBeAg Seroconversion', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '11', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA', 'description': 'Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir\\[ETV\\] 0.5 mg, tenofovir disoproxil fumarate\\[TDF\\] 245 mg, or tenofovir alafenamide\\[TAF\\] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2.'}, {'id': 'OG001', 'title': 'TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA', 'description': 'Participants who met the eligibility criteria for PegIFN-alpha2a (Participants who did not have disorders including but not limited to: autoimmune disorders, bone marrow suppression, hypoglycemia, hyperglycemia, diabetes mellitus) at Week 12 received combination treatment with JNJ-73763989 200 mg SC injection Q4W along with NA treatment (either ETV 0.5 mg, TDF 245 mg, or TAF 25 mg) QD up to Week 24 plus PegIFN-alpha 2a 180 micrograms (mcg) once weekly (QIW) during TP 2. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after Protocol Amendment 3, received JNJ-73763989 + PegIFN alpha 2a + NA only.'}, {'id': 'OG002', 'title': 'Follow-Up (FU) Period-nucleos(t)Ide Analog (NA)', 'description': 'At Week 24, prior to follow-up period, all participants stopped treatment with JNJ-73763989 + JNJ-56136379 + PegIFN-alpha2a. Participants who met the protocol-defined NA treatment completion criteria (hepatitis B surface antigen \\[HBsAg\\] \\<10 international units/millilitre \\[IU/mL\\], and hepatitis B e antigen \\[HBeAg\\]-negative, and hepatitis B virus deoxyribonucleic acid \\[HBV DNA\\] \\<20 IU/mL \\<lower limit of quantification \\[LLOQ\\], and alanine aminotransferase \\[ALT\\] \\<3\\*Upper limit of normal \\[ULN\\]) at Week 24, stopped NA at Week 26 (that is follow up Week 2). Participants who did not meet NA completion criteria continued NA treatment during the follow-up period up to follow-up Week 48 (with window period of +/- 4 days that is up to Week 72.4).'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '10.0', 'groupId': 'OG001'}, {'value': '20.0', 'groupId': 'OG002'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up Period: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'Percentage of participants with HBeAg seroconversion were reported. Seroconversion of HBeAg is defined as having achieved HBeAg seroclearance (as HBeAg level \\<LLOQ \\[0.11 IU/mL\\]) and appearance of anti-HBe antibodies, defined as baseline anti-HBe antibodies with a negative result and a post-baseline assessment with positive result.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all participants who were enrolled and who received at least 1 dose of study intervention within this ISA. Here "N" (Number of participants analyzed) signifies the number of participants that were evaluable for this outcome measure.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With HBsAg Seroconversion', 'denoms': [{'units': 'Participants', 'counts': [{'value': '45', 'groupId': 'OG000'}, {'value': '46', 'groupId': 'OG001'}, {'value': '46', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA', 'description': 'Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir\\[ETV\\] 0.5 mg, tenofovir disoproxil fumarate\\[TDF\\] 245 mg, or tenofovir alafenamide\\[TAF\\] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2.'}, {'id': 'OG001', 'title': 'TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA', 'description': 'Participants who met the eligibility criteria for PegIFN-alpha2a (Participants who did not have disorders including but not limited to: autoimmune disorders, bone marrow suppression, hypoglycemia, hyperglycemia, diabetes mellitus) at Week 12 received combination treatment with JNJ-73763989 200 mg SC injection Q4W along with NA treatment (either ETV 0.5 mg, TDF 245 mg, or TAF 25 mg) QD up to Week 24 plus PegIFN-alpha 2a 180 micrograms (mcg) once weekly (QIW) during TP 2. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after Protocol Amendment 3, received JNJ-73763989 + PegIFN alpha 2a + NA only.'}, {'id': 'OG002', 'title': 'Follow-Up (FU) Period-nucleos(t)Ide Analog (NA)', 'description': 'At Week 24, prior to follow-up period, all participants stopped treatment with JNJ-73763989 + JNJ-56136379 + PegIFN-alpha2a. Participants who met the protocol-defined NA treatment completion criteria (hepatitis B surface antigen \\[HBsAg\\] \\<10 international units/millilitre \\[IU/mL\\], and hepatitis B e antigen \\[HBeAg\\]-negative, and hepatitis B virus deoxyribonucleic acid \\[HBV DNA\\] \\<20 IU/mL \\<lower limit of quantification \\[LLOQ\\], and alanine aminotransferase \\[ALT\\] \\<3\\*Upper limit of normal \\[ULN\\]) at Week 24, stopped NA at Week 26 (that is follow up Week 2). Participants who did not meet NA completion criteria continued NA treatment during the follow-up period up to follow-up Week 48 (with window period of +/- 4 days that is up to Week 72.4).'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up Period: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'Percentage of participants with HBsAg seroconversion were reported. Seroconversion of HBsAg was defined as having achieved HBsAg seroclearance (defined as HBsAg \\<LLOQ \\[0.05 IU/mL\\]) and appearance of anti-HBs antibodies.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all participants who were enrolled and who received at least 1 dose of study intervention within this ISA. Here "N" (Number of participants analyzed) signifies the number of participants that were evaluable for this outcome measure.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline Over Time in HBsAg Levels', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '48', 'groupId': 'OG001'}, {'value': '48', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA', 'description': 'Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir\\[ETV\\] 0.5 mg, tenofovir disoproxil fumarate\\[TDF\\] 245 mg, or tenofovir alafenamide\\[TAF\\] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2.'}, {'id': 'OG001', 'title': 'TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA', 'description': 'Participants who met the eligibility criteria for PegIFN-alpha2a (Participants who did not have disorders including but not limited to: autoimmune disorders, bone marrow suppression, hypoglycemia, hyperglycemia, diabetes mellitus) at Week 12 received combination treatment with JNJ-73763989 200 mg SC injection Q4W along with NA treatment (either ETV 0.5 mg, TDF 245 mg, or TAF 25 mg) QD up to Week 24 plus PegIFN-alpha 2a 180 micrograms (mcg) once weekly (QIW) during TP 2. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after Protocol Amendment 3, received JNJ-73763989 + PegIFN alpha 2a + NA only.'}, {'id': 'OG002', 'title': 'Follow-Up (FU) Period-nucleos(t)Ide Analog (NA)', 'description': 'At Week 24, prior to follow-up period, all participants stopped treatment with JNJ-73763989 + JNJ-56136379 + PegIFN-alpha2a. Participants who met the protocol-defined NA treatment completion criteria (hepatitis B surface antigen \\[HBsAg\\] \\<10 international units/millilitre \\[IU/mL\\], and hepatitis B e antigen \\[HBeAg\\]-negative, and hepatitis B virus deoxyribonucleic acid \\[HBV DNA\\] \\<20 IU/mL \\<lower limit of quantification \\[LLOQ\\], and alanine aminotransferase \\[ALT\\] \\<3\\*Upper limit of normal \\[ULN\\]) at Week 24, stopped NA at Week 26 (that is follow up Week 2). Participants who did not meet NA completion criteria continued NA treatment during the follow-up period up to follow-up Week 48 (with window period of +/- 4 days that is up to Week 72.4).'}], 'classes': [{'categories': [{'measurements': [{'value': '-1.43', 'spread': '0.070', 'groupId': 'OG000', 'lowerLimit': '0.070'}, {'value': '-2.18', 'spread': '0.084', 'groupId': 'OG001', 'lowerLimit': '0.084'}, {'value': '-0.71', 'spread': '0.092', 'groupId': 'OG002', 'lowerLimit': '0.092'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Baseline (Day 1) up to Week 24; Follow-Up: From Baseline (Day 1) up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'Change from baseline over time in HBsAg levels were reported. The baseline assessment was defined as the last observed non-missing measurement before the date and time of the first administration of any of study agent.', 'unitOfMeasure': 'log10 IU/mL', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all participants who were enrolled and who received at least 1 dose of study intervention within this ISA.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline Over Time in HBeAg Levels', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '11', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA', 'description': 'Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir\\[ETV\\] 0.5 mg, tenofovir disoproxil fumarate\\[TDF\\] 245 mg, or tenofovir alafenamide\\[TAF\\] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2.'}, {'id': 'OG001', 'title': 'TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA', 'description': 'Participants who met the eligibility criteria for PegIFN-alpha2a (Participants who did not have disorders including but not limited to: autoimmune disorders, bone marrow suppression, hypoglycemia, hyperglycemia, diabetes mellitus) at Week 12 received combination treatment with JNJ-73763989 200 mg SC injection Q4W along with NA treatment (either ETV 0.5 mg, TDF 245 mg, or TAF 25 mg) QD up to Week 24 plus PegIFN-alpha 2a 180 micrograms (mcg) once weekly (QIW) during TP 2. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after Protocol Amendment 3, received JNJ-73763989 + PegIFN alpha 2a + NA only.'}, {'id': 'OG002', 'title': 'Follow-Up (FU) Period-nucleos(t)Ide Analog (NA)', 'description': 'At Week 24, prior to follow-up period, all participants stopped treatment with JNJ-73763989 + JNJ-56136379 + PegIFN-alpha2a. Participants who met the protocol-defined NA treatment completion criteria (hepatitis B surface antigen \\[HBsAg\\] \\<10 international units/millilitre \\[IU/mL\\], and hepatitis B e antigen \\[HBeAg\\]-negative, and hepatitis B virus deoxyribonucleic acid \\[HBV DNA\\] \\<20 IU/mL \\<lower limit of quantification \\[LLOQ\\], and alanine aminotransferase \\[ALT\\] \\<3\\*Upper limit of normal \\[ULN\\]) at Week 24, stopped NA at Week 26 (that is follow up Week 2). Participants who did not meet NA completion criteria continued NA treatment during the follow-up period up to follow-up Week 48 (with window period of +/- 4 days that is up to Week 72.4).'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.68', 'spread': '0.087', 'groupId': 'OG000', 'lowerLimit': '0.087'}, {'value': '-0.72', 'spread': '0.106', 'groupId': 'OG001', 'lowerLimit': '0.106'}, {'value': '-0.53', 'spread': '0.112', 'groupId': 'OG002', 'lowerLimit': '0.112'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Baseline (Day 1) up to Week 24; Follow-Up: From Baseline (Day 1) up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'Change from baseline over time in HBeAg levels were reported. The baseline assessment was defined as the last observed non-missing measurement before the date and time of the first administration of any of study agent.', 'unitOfMeasure': 'log10 IU/mL', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all participants who were enrolled and who received at least 1 dose of study intervention within this ISA. Here "N" (Number of participants analyzed) signifies the number of participants that were evaluable for this outcome measure.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline Over Time in HBV DNA Levels', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '48', 'groupId': 'OG001'}, {'value': '48', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA', 'description': 'Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir\\[ETV\\] 0.5 mg, tenofovir disoproxil fumarate\\[TDF\\] 245 mg, or tenofovir alafenamide\\[TAF\\] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2.'}, {'id': 'OG001', 'title': 'TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA', 'description': 'Participants who met the eligibility criteria for PegIFN-alpha2a (Participants who did not have disorders including but not limited to: autoimmune disorders, bone marrow suppression, hypoglycemia, hyperglycemia, diabetes mellitus) at Week 12 received combination treatment with JNJ-73763989 200 mg SC injection Q4W along with NA treatment (either ETV 0.5 mg, TDF 245 mg, or TAF 25 mg) QD up to Week 24 plus PegIFN-alpha 2a 180 micrograms (mcg) once weekly (QIW) during TP 2. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after Protocol Amendment 3, received JNJ-73763989 + PegIFN alpha 2a + NA only.'}, {'id': 'OG002', 'title': 'Follow-Up (FU) Period-nucleos(t)Ide Analog (NA)', 'description': 'At Week 24, prior to follow-up period, all participants stopped treatment with JNJ-73763989 + JNJ-56136379 + PegIFN-alpha2a. Participants who met the protocol-defined NA treatment completion criteria (hepatitis B surface antigen \\[HBsAg\\] \\<10 international units/millilitre \\[IU/mL\\], and hepatitis B e antigen \\[HBeAg\\]-negative, and hepatitis B virus deoxyribonucleic acid \\[HBV DNA\\] \\<20 IU/mL \\<lower limit of quantification \\[LLOQ\\], and alanine aminotransferase \\[ALT\\] \\<3\\*Upper limit of normal \\[ULN\\]) at Week 24, stopped NA at Week 26 (that is follow up Week 2). Participants who did not meet NA completion criteria continued NA treatment during the follow-up period up to follow-up Week 48 (with window period of +/- 4 days that is up to Week 72.4).'}], 'classes': [{'categories': [{'measurements': [{'value': '0.03', 'spread': '0.032', 'groupId': 'OG000'}, {'value': '0.28', 'spread': '0.059', 'groupId': 'OG001'}, {'value': '0.36', 'spread': '0.145', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Baseline (Day 1) up to Week 24; Follow-Up: From Baseline (Day 1) up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'Change from baseline over time in HBV DNA levels were reported. The baseline assessment was defined as the last observed non-missing measurement before the date and time of the first administration of any of study agent.', 'unitOfMeasure': 'log10 IU/mL', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all participants who were enrolled and who received at least 1 dose of study intervention within this ISA.'}, {'type': 'SECONDARY', 'title': 'Time to First Occurrence of HBsAg Seroclearance', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Pooled (JNJ-3989 200mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA)', 'description': 'Participants received JNJ-3989 200 mg as SC Q4W along with JNJ-6379 250 mg tablet QD and NA treatment (either ETV 0.5 mg, TDF 245 mg, or TAF 25 mg QD up to 12 weeks in TP1. At Week 12, participants who met eligibility criteria for PegIFN-alpha 2a entered TP2. Participants in TP2 received combination treatment of JNJ-3989 200 mg SC injection Q4W with NA treatment up to Week 24 plus PegIFN-alpha 2a 180 mcg Q1W. At Week 24, before follow-up period, participants stopped JNJ-3989 + JNJ-6379 + PegIFN-alpha2a. At Week 26, those who met the NA treatment completion criteria stopped NA (follow up Week 2) and those who did not meet criteria continued NA treatment in follow-up period up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4). Participants enrolled until Protocol Amendment 3 (PA3), also received JNJ-6379 250 mg orally as intervention in TP1 and TP2 and those enrolled after PA3, received only JNJ-3989 + PegIFN alpha 2a + NA during study.'}], 'classes': [{'categories': [{'measurements': [{'value': 'NA', 'comment': 'NA indicates that median \\[range\\] data were not estimable as at least 50% participants did not reach HBsAg seroclearance.', 'groupId': 'OG000', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'From Baseline (Day 1) up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'Time to first occurrence of HBsAg seroclearance were reported in median time. Time to first occurrence of the HBsAg seroclearance was defined as the number of days between the date of first study intervention intake and the date of first occurrence of the HBsAg seroclearance.', 'unitOfMeasure': 'weeks', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all participants who were enrolled and who received at least 1 dose of study intervention within this ISA. Data for this endpoint was planned to be collected and analyzed in a single arm.'}, {'type': 'SECONDARY', 'title': 'Time to First Occurrence of HBeAg Seroclearance', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Pooled (JNJ-3989 200mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA)', 'description': 'Participants received JNJ-3989 200 mg as SC Q4W along with JNJ-6379 250 mg tablet QD and NA treatment (either ETV 0.5 mg, TDF 245 mg, or TAF 25 mg QD up to 12 weeks in TP1. At Week 12, participants who met eligibility criteria for PegIFN-alpha 2a entered TP2. Participants in TP2 received combination treatment of JNJ-3989 200 mg SC injection Q4W with NA treatment up to Week 24 plus PegIFN-alpha 2a 180 mcg Q1W. At Week 24, before follow-up period, participants stopped JNJ-3989 + JNJ-6379 + PegIFN-alpha2a. At Week 26, those who met the NA treatment completion criteria stopped NA (follow up Week 2) and those who did not meet criteria continued NA treatment in follow-up period up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4). Participants enrolled until Protocol Amendment 3 (PA3), also received JNJ-6379 250 mg orally as intervention in TP1 and TP2 and those enrolled after PA3, received only JNJ-3989 + PegIFN alpha 2a + NA during study.'}], 'classes': [{'categories': [{'measurements': [{'value': '14.1', 'groupId': 'OG000', 'lowerLimit': '4.1', 'upperLimit': '72.4'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'From Baseline (Day 1) up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'Time to first occurrence of HBeAg seroclearance were reported in median time. Time to first occurrence of the HBeAg seroclearance is defined as the number of days between the date of first study intervention intake and the date of the first occurrence of the HBeAg seroclearance.', 'unitOfMeasure': 'weeks', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all participants who were enrolled and who received at least 1 dose of study intervention within this ISA. Here "N" (number of participants analyzed) signifies the number of participants that were evaluable for this outcome measure. Data for this outcome measure was planned to be collected and analyzed in a single arm.'}, {'type': 'SECONDARY', 'title': 'Time to First Occurrence of HBV DNA < LLOQ', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Pooled (JNJ-3989 200mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA)', 'description': 'Participants received JNJ-3989 200 mg as SC Q4W along with JNJ-6379 250 mg tablet QD and NA treatment (either ETV 0.5 mg, TDF 245 mg, or TAF 25 mg QD up to 12 weeks in TP1. At Week 12, participants who met eligibility criteria for PegIFN-alpha 2a entered TP2. Participants in TP2 received combination treatment of JNJ-3989 200 mg SC injection Q4W with NA treatment up to Week 24 plus PegIFN-alpha 2a 180 mcg Q1W. At Week 24, before follow-up period, participants stopped JNJ-3989 + JNJ-6379 + PegIFN-alpha2a. At Week 26, those who met the NA treatment completion criteria stopped NA (follow up Week 2) and those who did not meet criteria continued NA treatment in follow-up period up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4). Participants enrolled until Protocol Amendment 3 (PA3), also received JNJ-6379 250 mg orally as intervention in TP1 and TP2 and those enrolled after PA3, received only JNJ-3989 + PegIFN alpha 2a + NA during study.'}], 'classes': [{'categories': [{'measurements': [{'value': '4.1', 'groupId': 'OG000', 'lowerLimit': '2.9', 'upperLimit': '32.3'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'From Baseline (Day 1) up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'Time to first occurrence of HBV DNA \\< LLOQ (20 IU/mL) were reported in median time. Time to first occurrence of the HBV DNA \\< LLOQ is defined as the number of days between the date of first study intervention intake and the date of the first occurrence of the HBV DNA \\< LLOQ.', 'unitOfMeasure': 'weeks', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all participants who were enrolled and who received at least 1 dose of study intervention within this ISA. Data for this endpoint was planned to be collected and analyzed in a single arm.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Virologic Breakthrough', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '48', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA', 'description': 'Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir\\[ETV\\] 0.5 mg, tenofovir disoproxil fumarate\\[TDF\\] 245 mg, or tenofovir alafenamide\\[TAF\\] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2.'}, {'id': 'OG001', 'title': 'TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA', 'description': 'Participants who met the eligibility criteria for PegIFN-alpha2a (Participants who did not have disorders including but not limited to: autoimmune disorders, bone marrow suppression, hypoglycemia, hyperglycemia, diabetes mellitus) at Week 12 received combination treatment with JNJ-73763989 200 mg SC injection Q4W along with NA treatment (either ETV 0.5 mg, TDF 245 mg, or TAF 25 mg) QD up to Week 24 plus PegIFN-alpha 2a 180 micrograms (mcg) once weekly (QIW) during TP 2. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after Protocol Amendment 3, received JNJ-73763989 + PegIFN alpha 2a + NA only.'}, {'id': 'OG002', 'title': 'Follow-Up (FU) Period-nucleos(t)Ide Analog (NA)', 'description': 'At Week 24, prior to follow-up period, all participants stopped treatment with JNJ-73763989 + JNJ-56136379 + PegIFN-alpha2a. Participants who met the protocol-defined NA treatment completion criteria (hepatitis B surface antigen \\[HBsAg\\] \\<10 international units/millilitre \\[IU/mL\\], and hepatitis B e antigen \\[HBeAg\\]-negative, and hepatitis B virus deoxyribonucleic acid \\[HBV DNA\\] \\<20 IU/mL \\<lower limit of quantification \\[LLOQ\\], and alanine aminotransferase \\[ALT\\] \\<3\\*Upper limit of normal \\[ULN\\]) at Week 24, stopped NA at Week 26 (that is follow up Week 2). Participants who did not meet NA completion criteria continued NA treatment during the follow-up period up to follow-up Week 48 (with window period of +/- 4 days that is up to Week 72.4).'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'Percentage of Participants with virologic breakthrough were reported. It was defined as confirmed on-treatment (the time period during which the participant received any of the study treatments) HBV DNA increase by \\>1 log10 IU/mL from nadir or confirmed on-treatment HBV DNA level \\>200 IU/mL in participants who had HBV DNA level \\<LLOQ (20 IU/mL) of the HBV DNA assay. Confirmed means that the criteria were fulfilled at 2 or more consecutive time points or at the last observed time point.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all participants who were enrolled and who received at least 1 dose of study intervention within this ISA. Here "N" (Number of participants analyzed) signifies the number of participants that were evaluable for this outcome measure.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With HBsAg Seroclearance at Week 48 Without Re-starting NA Treatment', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Follow-Up (FU) Period-nucleos(t)Ide Analog (NA)', 'description': 'At Week 24, prior to follow-up period, all participants stopped treatment with JNJ-73763989 + JNJ-56136379 + PegIFN-alpha2a. Participants who met the protocol-defined NA treatment completion criteria (hepatitis B surface antigen \\[HBsAg\\] \\<10 international units/millilitre \\[IU/mL\\], and hepatitis B e antigen \\[HBeAg\\]-negative, and hepatitis B virus deoxyribonucleic acid \\[HBV DNA\\] \\<20 IU/mL \\<lower limit of quantification \\[LLOQ\\], and alanine aminotransferase \\[ALT\\] \\<3\\*Upper limit of normal \\[ULN\\]) at Week 24, stopped NA at Week 26 (that is follow up Week 2). Participants who did not meet NA completion criteria continued NA treatment during the follow-up period up to follow-up Week 48 (with window period of +/- 4 days that is up to Week 72.4).'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'At Week 48 (24 weeks after completion of all study interventions at Week 24)', 'description': 'Percentage of participants with HBsAg seroclearance at Week 48 (i.e., 24 weeks after completion of all study interventions at Week 24) without re-starting NA treatment were reported. HBsAg seroclearance was defined as \\[quantitative\\] HBsAg \\<LLOQ (0.05 IU/mL).', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all participants who were enrolled and who received at least 1 dose of study intervention within this ISA. Data for this outcome measure was planned to be collected and analyzed for Follow-Up Period only as pre-specified in protocol.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With HBV DNA < LLOQ at Week 48 Without Re-starting NA Treatment', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Follow-Up (FU) Period-nucleos(t)Ide Analog (NA)', 'description': 'At Week 24, prior to follow-up period, all participants stopped treatment with JNJ-73763989 + JNJ-56136379 + PegIFN-alpha2a. Participants who met the protocol-defined NA treatment completion criteria (hepatitis B surface antigen \\[HBsAg\\] \\<10 international units/millilitre \\[IU/mL\\], and hepatitis B e antigen \\[HBeAg\\]-negative, and hepatitis B virus deoxyribonucleic acid \\[HBV DNA\\] \\<20 IU/mL \\<lower limit of quantification \\[LLOQ\\], and alanine aminotransferase \\[ALT\\] \\<3\\*Upper limit of normal \\[ULN\\]) at Week 24, stopped NA at Week 26 (that is follow up Week 2). Participants who did not meet NA completion criteria continued NA treatment during the follow-up period up to follow-up Week 48 (with window period of +/- 4 days that is up to Week 72.4).'}], 'classes': [{'categories': [{'measurements': [{'value': '30.0', 'groupId': 'OG000'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'At Week 48 (24 weeks after completion of all study interventions at Week 24)', 'description': 'Percentage of participants with HBV DNA \\<LLOQ (20 IU/mL) at Week 48 (that is, 24 weeks after completion of all study interventions at Week 24) without re-starting NA treatment were reported.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all participants who were enrolled and who received at least 1 dose of study intervention within this ISA. Here "N" (Number of participants analyzed) signifies the number of participants that were evaluable for this outcome measure. Data for this outcome measure was planned to be collected and analyzed for Follow-Up Period only as pre specified in protocol.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Biochemical Flares', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '48', 'groupId': 'OG001'}, {'value': '48', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA', 'description': 'Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir\\[ETV\\] 0.5 mg, tenofovir disoproxil fumarate\\[TDF\\] 245 mg, or tenofovir alafenamide\\[TAF\\] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2.'}, {'id': 'OG001', 'title': 'TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA', 'description': 'Participants who met the eligibility criteria for PegIFN-alpha2a (Participants who did not have disorders including but not limited to: autoimmune disorders, bone marrow suppression, hypoglycemia, hyperglycemia, diabetes mellitus) at Week 12 received combination treatment with JNJ-73763989 200 mg SC injection Q4W along with NA treatment (either ETV 0.5 mg, TDF 245 mg, or TAF 25 mg) QD up to Week 24 plus PegIFN-alpha 2a 180 micrograms (mcg) once weekly (QIW) during TP 2. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after Protocol Amendment 3, received JNJ-73763989 + PegIFN alpha 2a + NA only.'}, {'id': 'OG002', 'title': 'Follow-Up (FU) Period-nucleos(t)Ide Analog (NA)', 'description': 'At Week 24, prior to follow-up period, all participants stopped treatment with JNJ-73763989 + JNJ-56136379 + PegIFN-alpha2a. Participants who met the protocol-defined NA treatment completion criteria (hepatitis B surface antigen \\[HBsAg\\] \\<10 international units/millilitre \\[IU/mL\\], and hepatitis B e antigen \\[HBeAg\\]-negative, and hepatitis B virus deoxyribonucleic acid \\[HBV DNA\\] \\<20 IU/mL \\<lower limit of quantification \\[LLOQ\\], and alanine aminotransferase \\[ALT\\] \\<3\\*Upper limit of normal \\[ULN\\]) at Week 24, stopped NA at Week 26 (that is follow up Week 2). Participants who did not meet NA completion criteria continued NA treatment during the follow-up period up to follow-up Week 48 (with window period of +/- 4 days that is up to Week 72.4).'}], 'classes': [{'title': 'On-Treatment', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '48', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000', 'lowerLimit': '0', 'upperLimit': '6.05'}, {'value': '4.2', 'groupId': 'OG001', 'lowerLimit': '0.75', 'upperLimit': '12.54'}, {'value': '0', 'groupId': 'OG002', 'lowerLimit': '0', 'upperLimit': '7.58'}]}]}, {'title': 'Off-Treatment', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '15', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG002', 'lowerLimit': '0', 'upperLimit': '0'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'Percentage of participants with biochemical flares were reported. On-treatment biochemical flare was defined as confirmed ALT and/or AST \\>=3\\*ULN and \\>=3\\*nadir, while the participant received any of the study interventions. Off-treatment biochemical flare was defined as confirmed ALT and/or AST =3\\*ULN and =3\\*nadir, while the participants did not receive any of the study interventions (Off treatment, including NA).', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '90% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all participants who were enrolled and who received at least 1 dose of study intervention within this ISA. Here "N" (Number of participants analyzed) signifies the number of participants that were evaluable for this outcome measure and "n"(number analyzed) signifies number of participants analyzed at specified categories. No participant was available for the analysis where "n=0".'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Virologic Flares', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Follow-Up (FU) Period-nucleos(t)Ide Analog (NA)', 'description': 'At Week 24, prior to follow-up period, all participants stopped treatment with JNJ-73763989 + JNJ-56136379 + PegIFN-alpha2a. Participants who met the protocol-defined NA treatment completion criteria (hepatitis B surface antigen \\[HBsAg\\] \\<10 international units/millilitre \\[IU/mL\\], and hepatitis B e antigen \\[HBeAg\\]-negative, and hepatitis B virus deoxyribonucleic acid \\[HBV DNA\\] \\<20 IU/mL \\<lower limit of quantification \\[LLOQ\\], and alanine aminotransferase \\[ALT\\] \\<3\\*Upper limit of normal \\[ULN\\]) at Week 24, stopped NA at Week 26 (that is follow up Week 2). Participants who did not meet NA completion criteria continued NA treatment during the follow-up period up to follow-up Week 48 (with window period of +/- 4 days that is up to Week 72.4).'}], 'classes': [{'categories': [{'measurements': [{'value': '33.3', 'spread': '14.17', 'groupId': 'OG000', 'lowerLimit': '14.17', 'upperLimit': '57.74'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Follow-Up Period: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'Percentage of participants with virologic flares were reported. Virologic flare was defined as confirmed HBV DNA \\>peak threshold (lowest peak to qualify as virologic flare was HBV DNA \\>200 IU/mL) in participants who were off-treatment. Off-treatment was defined as the time period after stopping all study treatments (including NA) and had HBV DNA \\<LLOQ (20 IU/mL) at the last observed time point on all study interventions.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '90% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all participants who were enrolled and who received at least 1 dose of study intervention within this ISA. Here "N" (Number of participants analyzed) signifies the number of participants that were evaluable for this outcome measure. Data for this outcome measure was planned to be collected and analyzed for Follow-Up period only as pre-specified in protocol.'}, {'type': 'SECONDARY', 'title': 'Number of Participants Requiring NA Re-treatment', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Follow-Up (FU) Period-nucleos(t)Ide Analog (NA)', 'description': 'At Week 24, prior to follow-up period, all participants stopped treatment with JNJ-73763989 + JNJ-56136379 + PegIFN-alpha2a. Participants who met the protocol-defined NA treatment completion criteria (hepatitis B surface antigen \\[HBsAg\\] \\<10 international units/millilitre \\[IU/mL\\], and hepatitis B e antigen \\[HBeAg\\]-negative, and hepatitis B virus deoxyribonucleic acid \\[HBV DNA\\] \\<20 IU/mL \\<lower limit of quantification \\[LLOQ\\], and alanine aminotransferase \\[ALT\\] \\<3\\*Upper limit of normal \\[ULN\\]) at Week 24, stopped NA at Week 26 (that is follow up Week 2). Participants who did not meet NA completion criteria continued NA treatment during the follow-up period up to follow-up Week 48 (with window period of +/- 4 days that is up to Week 72.4).'}], 'classes': [{'categories': [{'measurements': [{'value': '4', 'groupId': 'OG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Follow-Up Period: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'Number of participants requiring NA re-treatment based on failure in NA treatment completion criteria (HBsAg \\<10 IU/mL, and HBeAg-negative, and HBV DNA \\< LLOQ (20 IU/mL), and ALT \\<3\\*ULN) were reported.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all participants who were enrolled and who received at least 1 dose of study intervention within this ISA. Here "N" (Number of participants analyzed) signifies the number of participants that were evaluable for this outcome measure. Data for this outcome measure was planned to be collected and analyzed for Follow-up Period only as pre-specified in protocol.'}, {'type': 'SECONDARY', 'title': 'Maximum Observed Plasma Concentration (Cmax) of JNJ-73763989 (JNJ-73763976 and JNJ-73763924)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA', 'description': 'Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir\\[ETV\\] 0.5 mg, tenofovir disoproxil fumarate\\[TDF\\] 245 mg, or tenofovir alafenamide\\[TAF\\] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2.'}, {'id': 'OG001', 'title': 'TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA', 'description': 'Participants who met the eligibility criteria for PegIFN-alpha2a (Participants who did not have disorders including but not limited to: autoimmune disorders, bone marrow suppression, hypoglycemia, hyperglycemia, diabetes mellitus) at Week 12 received combination treatment with JNJ-73763989 200 mg SC injection Q4W along with NA treatment (either ETV 0.5 mg, TDF 245 mg, or TAF 25 mg) QD up to Week 24 plus PegIFN-alpha 2a 180 micrograms (mcg) once weekly (QIW) during TP 2. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after Protocol Amendment 3, received JNJ-73763989 + PegIFN alpha 2a + NA only.'}], 'classes': [{'title': 'JNJ-73763976', 'categories': [{'measurements': [{'value': '1338', 'spread': '971', 'groupId': 'OG000'}, {'value': '928', 'spread': '692', 'groupId': 'OG001'}]}]}, {'title': 'JNJ-73763924', 'categories': [{'measurements': [{'value': '271', 'spread': '197', 'groupId': 'OG000'}, {'value': '185', 'spread': '130', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Treatment Period 1: Day 1 Week 1; Treatment Period 2: Day 1, Week 12', 'description': 'The maximum observed plasma concentrations (Cmax) of JNJ-73763989 (JNJ-73763976 and JNJ-73763924) were reported.', 'unitOfMeasure': 'nanograms/milliliters (ng/mL)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Pharmacokinetics(PK) analysis set included participants who received at least 1 dose of study intervention and had at least 1 valid blood sample drawn for PK analysis. Here "N" (Number of participants analyzed) signifies the number of participants that were evaluable for this outcome measure. Data for this outcome measure was planned to be collected and analyzed for TP1 and TP2 only as specified in protocol.'}, {'type': 'SECONDARY', 'title': 'Plasma Concentration 24 Hours After Administration (C24h) of JNJ-73763989 (JNJ-73763976 and JNJ-73763924)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA', 'description': 'Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir\\[ETV\\] 0.5 mg, tenofovir disoproxil fumarate\\[TDF\\] 245 mg, or tenofovir alafenamide\\[TAF\\] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2.'}, {'id': 'OG001', 'title': 'TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA', 'description': 'Participants who met the eligibility criteria for PegIFN-alpha2a (Participants who did not have disorders including but not limited to: autoimmune disorders, bone marrow suppression, hypoglycemia, hyperglycemia, diabetes mellitus) at Week 12 received combination treatment with JNJ-73763989 200 mg SC injection Q4W along with NA treatment (either ETV 0.5 mg, TDF 245 mg, or TAF 25 mg) QD up to Week 24 plus PegIFN-alpha 2a 180 micrograms (mcg) once weekly (QIW) during TP 2. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after Protocol Amendment 3, received JNJ-73763989 + PegIFN alpha 2a + NA only.'}], 'classes': [{'title': 'JNJ-73763976', 'categories': [{'measurements': [{'value': '309', 'spread': '145', 'groupId': 'OG000'}, {'value': '390', 'spread': '162', 'groupId': 'OG001'}]}]}, {'title': 'JNJ-73763924', 'categories': [{'measurements': [{'value': '38.7', 'spread': '16.2', 'groupId': 'OG000'}, {'value': '57.4', 'spread': '15.9', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Treatment Period 1: Day 1 Week 1; Treatment Period 2: Day 1, Week 12', 'description': 'Plasma concentration 24 hours (C24h) after administration of JNJ-73763989 (JNJ-73763976 and JNJ-73763924) were reported.', 'unitOfMeasure': 'ng/mL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Analysis Set included all participants who received at least 1 dose of study intervention and had at least 1 valid blood sample drawn for PK analysis. Here "N" (Number of participants analyzed) signifies the number of participants that were evaluable for this outcome measure. Data for this outcome measure was planned to be collected and analyzed for TP 1 and TP 2 as pre-specified in protocol.'}, {'type': 'SECONDARY', 'title': 'Time to Reach Maximum Observed Plasma Concentration (Tmax) of JNJ-73763989 (JNJ-73763976 and JNJ-73763924)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA', 'description': 'Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir\\[ETV\\] 0.5 mg, tenofovir disoproxil fumarate\\[TDF\\] 245 mg, or tenofovir alafenamide\\[TAF\\] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2.'}, {'id': 'OG001', 'title': 'TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA', 'description': 'Participants who met the eligibility criteria for PegIFN-alpha2a (Participants who did not have disorders including but not limited to: autoimmune disorders, bone marrow suppression, hypoglycemia, hyperglycemia, diabetes mellitus) at Week 12 received combination treatment with JNJ-73763989 200 mg SC injection Q4W along with NA treatment (either ETV 0.5 mg, TDF 245 mg, or TAF 25 mg) QD up to Week 24 plus PegIFN-alpha 2a 180 micrograms (mcg) once weekly (QIW) during TP 2. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after Protocol Amendment 3, received JNJ-73763989 + PegIFN alpha 2a + NA only.'}], 'classes': [{'title': 'JNJ-73763976', 'categories': [{'measurements': [{'value': '5.50', 'groupId': 'OG000', 'lowerLimit': '2.00', 'upperLimit': '6.20'}, {'value': '6.00', 'groupId': 'OG001', 'lowerLimit': '2.00', 'upperLimit': '23.58'}]}]}, {'title': 'JNJ-73763924', 'categories': [{'measurements': [{'value': '2.00', 'groupId': 'OG000', 'lowerLimit': '1.00', 'upperLimit': '6.00'}, {'value': '4.02', 'groupId': 'OG001', 'lowerLimit': '0.50', 'upperLimit': '7.72'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Treatment Period 1: Day 1, Week 1; Treatment Period 2: Day 1, Week 12', 'description': 'Time to reach maximum observed plasma concentration (Cmax) (Tmax) of JNJ-73763989 (JNJ-73763976 and JNJ-73763924) were reported.', 'unitOfMeasure': 'hours', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'PK analysis set included all participants who received at least 1 dose of study intervention and had at least 1 valid blood sample drawn for PK analysis. Here "N" (Number of participants analyzed) signifies the number of participants that were evaluable for this outcome measure. Data for this outcome measure was planned to be collected and analyzed for TP1 and TP2 as pre-specified in protocol.'}, {'type': 'SECONDARY', 'title': 'Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hour (AUC[0-24]h) of JNJ-73763989 (JNJ-73763976 and JNJ-73763924)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA', 'description': 'Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir\\[ETV\\] 0.5 mg, tenofovir disoproxil fumarate\\[TDF\\] 245 mg, or tenofovir alafenamide\\[TAF\\] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2.'}, {'id': 'OG001', 'title': 'TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA', 'description': 'Participants who met the eligibility criteria for PegIFN-alpha2a (Participants who did not have disorders including but not limited to: autoimmune disorders, bone marrow suppression, hypoglycemia, hyperglycemia, diabetes mellitus) at Week 12 received combination treatment with JNJ-73763989 200 mg SC injection Q4W along with NA treatment (either ETV 0.5 mg, TDF 245 mg, or TAF 25 mg) QD up to Week 24 plus PegIFN-alpha 2a 180 micrograms (mcg) once weekly (QIW) during TP 2. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after Protocol Amendment 3, received JNJ-73763989 + PegIFN alpha 2a + NA only.'}], 'classes': [{'title': 'JNJ-73763976', 'categories': [{'measurements': [{'value': '18635', 'spread': '10983', 'groupId': 'OG000'}, {'value': '13580', 'spread': '8598', 'groupId': 'OG001'}]}]}, {'title': 'JNJ-73763924', 'categories': [{'measurements': [{'value': '3342', 'spread': '1919', 'groupId': 'OG000'}, {'value': '2466', 'spread': '1432', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Treatment Period 1: Day 1, Week 1; Treatment Period 2: Day 1, Week 12', 'description': 'Area under the plasma concentration versus time curve from time 0 to 24 hours (AUC\\[0-24\\]h) of JNJ-73763989 (JNJ-73763976 and JNJ-73763924) were reported.', 'unitOfMeasure': 'ng*h/mL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK analysis set: participants who received at least 1 dose of study intervention and had at least 1 valid blood sample drawn for PK analysis. Here "N" (number of participants analyzed) signifies the number of participants that were evaluable for this outcome measure. Data for this outcome measure was planned to be collected and analyzed for TP1 and TP2 as specified in protocol.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA', 'description': 'Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir\\[ETV\\] 0.5 mg, tenofovir disoproxil fumarate\\[TDF\\] 245 mg, or tenofovir alafenamide\\[TAF\\] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2.'}, {'id': 'FG001', 'title': 'TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA', 'description': 'Participants who met the eligibility criteria for PegIFN-alpha2a (Participants who did not have disorders including but not limited to: autoimmune disorders, bone marrow suppression, hypoglycemia, hyperglycemia, diabetes mellitus) at Week 12 received combination treatment with JNJ-73763989 200 mg SC injection Q4W along with NA treatment (either ETV 0.5 mg, TDF 245 mg, or TAF 25 mg) QD up to Week 24 plus PegIFN-alpha 2a 180 micrograms (mcg) once weekly (QIW) during TP 2. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after Protocol Amendment 3, received JNJ-73763989 + PegIFN alpha 2a + NA only.'}, {'id': 'FG002', 'title': 'Follow-Up (FU) Period-nucleos(t)Ide Analog (NA)', 'description': 'At Week 24, prior to follow-up period, all participants stopped treatment with JNJ-73763989 + JNJ-56136379 + PegIFN-alpha2a. Participants who met the protocol-defined NA treatment completion criteria (hepatitis B surface antigen \\[HBsAg\\] \\<10 international units/millilitre \\[IU/mL\\], and hepatitis B e antigen \\[HBeAg\\]-negative, and hepatitis B virus deoxyribonucleic acid \\[HBV DNA\\] \\<20 IU/mL \\<lower limit of quantification \\[LLOQ\\], and alanine aminotransferase \\[ALT\\] \\<3\\*Upper limit of normal \\[ULN\\]) at Week 24, stopped NA at Week 26 (that is follow up Week 2). Participants who did not meet NA completion criteria continued NA treatment during the follow-up period up to follow-up Week 48 (with window period of +/- 4 days that is up to Week 72.4).'}], 'periods': [{'title': 'TP 1: From Week 1 to Week 12', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '48'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '48'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}]}]}, {'title': 'TP 2: From Week 12 to Week 24', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '48'}, {'groupId': 'FG002', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '48'}, {'groupId': 'FG002', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}]}]}, {'title': 'FU:Week 24 to FU Week 48 (i.e.Week 72.4)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '48'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '47'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '1'}]}], 'dropWithdraws': [{'type': 'Other', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '1'}]}]}], 'preAssignmentDetails': 'At Week 12, participants were assessed for pegylated interferon alpha 2a (PegIFN-alpha2a) eligibility criteria and those who did not meet the criteria continued in Treatment Period 1 (TP 1) until Week 24 and those who met the criteria entered Treatment Period 2 (TP 2). After Week 12, one participant continued with TP1 regimen during TP2 until Week 24. As of Protocol Amendment 3, JNJ-56136379 was stopped immediately as study drug and study continued with JNJ-73763989, PegIFN alpha 2a \\& NA only.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'BG000'}]}], 'groups': [{'id': 'BG000', 'title': 'TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA', 'description': 'Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir\\[ETV\\] 0.5 mg, tenofovir disoproxil fumarate\\[TDF\\] 245 mg, or tenofovir alafenamide\\[TAF\\] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2.'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '44.6', 'spread': '1.47', 'groupId': 'BG000', 'lowerLimit': '1.47'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Age, Customized', 'classes': [{'categories': [{'title': 'Children (2-11 years)', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Adolescents (12-17 years)', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Adults (18-64 years)', 'measurements': [{'value': '48', 'groupId': 'BG000'}]}, {'title': 'From 65 to 84 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': '85 years and over', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '8', 'groupId': 'BG000'}]}, {'title': 'Male', 'measurements': [{'value': '40', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '48', 'groupId': 'BG000'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Asian', 'measurements': [{'value': '34', 'groupId': 'BG000'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Black or African American', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'White', 'measurements': [{'value': '14', 'groupId': 'BG000'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2021-12-01', 'size': 8258836, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2024-04-17T07:29', 'hasProtocol': True}, {'date': '2023-05-18', 'size': 1802708, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2024-04-17T07:29', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 48}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2021-02-01', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-06', 'dispFirstSubmitDate': '2023-05-15', 'completionDateStruct': {'date': '2023-04-17', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-06-06', 'studyFirstSubmitDate': '2020-12-09', 'resultsFirstSubmitDate': '2024-04-17', 'studyFirstSubmitQcDate': '2020-12-09', 'dispFirstPostDateStruct': {'date': '2024-07-03', 'type': 'ACTUAL'}, 'lastUpdatePostDateStruct': {'date': '2024-07-03', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2024-06-06', 'studyFirstPostDateStruct': {'date': '2020-12-14', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2024-07-03', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2022-05-16', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Percentage of Participants With a Reduction of at Least 2 log10 International Unit/Millilitres (IU/mL) in Hepatitis B Surface Antigen (HBsAg) Levels From Baseline to Week 24', 'timeFrame': 'From Baseline (Day 1) to Week 24', 'description': 'Percentage of participants with a reduction of at least 2 log10IU/mL in HBsAg levels from baseline to Week 24 were reported. A responder was defined as a participant with reduction of at least 2 log10 IU/mL in HBsAg levels from baseline at Week 24.'}], 'secondaryOutcomes': [{'measure': 'Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) as a Measure of Safety and Tolerability', 'timeFrame': 'Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up Period: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'Percentage of participants with TEAEs were reported. An adverse event (AE) was any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs were AEs with onset during the intervention period or follow-up period or that were a consequence of a pre-existing condition that had worsened since baseline.'}, {'measure': 'Percentage of Participants With Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability', 'timeFrame': 'Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up Period: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs were AEs with onset during the intervention period or follow-up period or that were a consequence of a pre-existing condition that had worsened since baseline. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.'}, {'measure': 'Number of Participants With Clinically Significant Abnormalities in Vital Signs as a Measure of Safety and Tolerability', 'timeFrame': 'Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up Period: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'Number of participants with clinically significant abnormalities in vital signs (pulse rate, and blood pressure \\[systolic and diastolic\\]) were reported.'}, {'measure': 'Number of Participants With Clinically Significant Abnormalities in Laboratory Findings as a Measure of Safety and Tolerability', 'timeFrame': 'Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up Period: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'Number of participants with clinically significant abnormalities in laboratory findings (including hematology, blood biochemistry, and urinalysis) were reported. Only parameters in which any participant had abnormality are reported below.'}, {'measure': 'Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECGs) as a Measure of Safety and Tolerability', 'timeFrame': 'Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up Period: From Week 24 up to Week 28', 'description': 'Number of participants with clinically significant abnormalities in 12- lead ECGs (heart rate, PR, QRS and QT corrected \\[QTc\\]) were reported.'}, {'measure': 'Number of Participants With Clinically Significant Abnormalities in Physical Examination as a Measure of Safety and Tolerability', 'timeFrame': 'Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24', 'description': 'Number of participants with clinically significant abnormalities in physical examination were reported.'}, {'measure': 'Number of Participants With Abnormalities in Ophthalmic Examination as a Measure of Safety and Tolerability', 'timeFrame': 'Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24', 'description': 'Number of participants with abnormalities in Ophthalmic examination were planned to be reported.'}, {'measure': 'Percentage of Participants Meeting the Protocol-defined Nucleos(t)Ide Analog (NA) Treatment Completion Criteria at End of Study Intervention (EOSI)', 'timeFrame': 'At Week 24 (EOSI)', 'description': 'Percentage of participants meeting the protocol-defined NA treatment completion criteria at EOSI were reported. NA treatment completion criteria are defined based on laboratory results at Week 24 were; HBsAg \\<10 IU/mL; HBeAg-negative; HBV DNA \\<20 IU/mL, that is, lower limit of quantification(LLOQ); alanine aminotransferase(ALT) \\<3\\*ULN.'}, {'measure': 'Percentage of Participants With Hepatitis B e Antigen (HBeAg) Levels Below Different Cut-offs', 'timeFrame': 'Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up Period: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'Percentage of participants with HBeAg levels below different cut-offs were reported. The cut-offs for HBeAg levels were as followed:\\< 100 IU/mL, \\< 10 IU/mL, \\< 1 IU/mL, \\< LLOQ (0.11 IU/mL).'}, {'measure': 'Percentage of Participants With HBsAg Levels Below Different Cut-offs', 'timeFrame': 'Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up Period: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'Percentage of participants with HBsAg levels below different cut-offs were reported. The cut-offs for HBsAg level were: \\<1000 IU/mL, \\<100 IU/mL, \\<10 IU/mL, \\<1 IU/mL, \\<LLOQ (0.05 IU/mL).'}, {'measure': 'Percentage of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels Below Different Cut-offs', 'timeFrame': 'Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up Period: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'Percentage of participants with HBV DNA levels below cut-offs were reported. The cut-offs for HBV DNA were as follows: \\<LLOQ (=20 IU/mL) target detected or not detected, \\< LLOQ target not detected, and \\< LLOQ target detected, \\<60 IU/mL, \\<100 IU/mL, \\<200 IU/mL, \\<1000 IU/mL, \\<2000 IU/mL, \\<20000 IU/mL.'}, {'measure': 'Percentage of Participants With ALT Levels Greater Than or Equal to (>=) 3*ULN', 'timeFrame': 'Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up Period: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'Percentage of participants with ALT levels below \\>=3\\*ULN cut-off were reported.'}, {'measure': 'Percentage of Participants With HBeAg Seroconversion', 'timeFrame': 'Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up Period: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'Percentage of participants with HBeAg seroconversion were reported. Seroconversion of HBeAg is defined as having achieved HBeAg seroclearance (as HBeAg level \\<LLOQ \\[0.11 IU/mL\\]) and appearance of anti-HBe antibodies, defined as baseline anti-HBe antibodies with a negative result and a post-baseline assessment with positive result.'}, {'measure': 'Percentage of Participants With HBsAg Seroconversion', 'timeFrame': 'Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up Period: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'Percentage of participants with HBsAg seroconversion were reported. Seroconversion of HBsAg was defined as having achieved HBsAg seroclearance (defined as HBsAg \\<LLOQ \\[0.05 IU/mL\\]) and appearance of anti-HBs antibodies.'}, {'measure': 'Change From Baseline Over Time in HBsAg Levels', 'timeFrame': 'Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Baseline (Day 1) up to Week 24; Follow-Up: From Baseline (Day 1) up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'Change from baseline over time in HBsAg levels were reported. The baseline assessment was defined as the last observed non-missing measurement before the date and time of the first administration of any of study agent.'}, {'measure': 'Change From Baseline Over Time in HBeAg Levels', 'timeFrame': 'Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Baseline (Day 1) up to Week 24; Follow-Up: From Baseline (Day 1) up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'Change from baseline over time in HBeAg levels were reported. The baseline assessment was defined as the last observed non-missing measurement before the date and time of the first administration of any of study agent.'}, {'measure': 'Change From Baseline Over Time in HBV DNA Levels', 'timeFrame': 'Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Baseline (Day 1) up to Week 24; Follow-Up: From Baseline (Day 1) up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'Change from baseline over time in HBV DNA levels were reported. The baseline assessment was defined as the last observed non-missing measurement before the date and time of the first administration of any of study agent.'}, {'measure': 'Time to First Occurrence of HBsAg Seroclearance', 'timeFrame': 'From Baseline (Day 1) up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'Time to first occurrence of HBsAg seroclearance were reported in median time. Time to first occurrence of the HBsAg seroclearance was defined as the number of days between the date of first study intervention intake and the date of first occurrence of the HBsAg seroclearance.'}, {'measure': 'Time to First Occurrence of HBeAg Seroclearance', 'timeFrame': 'From Baseline (Day 1) up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'Time to first occurrence of HBeAg seroclearance were reported in median time. Time to first occurrence of the HBeAg seroclearance is defined as the number of days between the date of first study intervention intake and the date of the first occurrence of the HBeAg seroclearance.'}, {'measure': 'Time to First Occurrence of HBV DNA < LLOQ', 'timeFrame': 'From Baseline (Day 1) up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'Time to first occurrence of HBV DNA \\< LLOQ (20 IU/mL) were reported in median time. Time to first occurrence of the HBV DNA \\< LLOQ is defined as the number of days between the date of first study intervention intake and the date of the first occurrence of the HBV DNA \\< LLOQ.'}, {'measure': 'Percentage of Participants With Virologic Breakthrough', 'timeFrame': 'Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'Percentage of Participants with virologic breakthrough were reported. It was defined as confirmed on-treatment (the time period during which the participant received any of the study treatments) HBV DNA increase by \\>1 log10 IU/mL from nadir or confirmed on-treatment HBV DNA level \\>200 IU/mL in participants who had HBV DNA level \\<LLOQ (20 IU/mL) of the HBV DNA assay. Confirmed means that the criteria were fulfilled at 2 or more consecutive time points or at the last observed time point.'}, {'measure': 'Percentage of Participants With HBsAg Seroclearance at Week 48 Without Re-starting NA Treatment', 'timeFrame': 'At Week 48 (24 weeks after completion of all study interventions at Week 24)', 'description': 'Percentage of participants with HBsAg seroclearance at Week 48 (i.e., 24 weeks after completion of all study interventions at Week 24) without re-starting NA treatment were reported. HBsAg seroclearance was defined as \\[quantitative\\] HBsAg \\<LLOQ (0.05 IU/mL).'}, {'measure': 'Percentage of Participants With HBV DNA < LLOQ at Week 48 Without Re-starting NA Treatment', 'timeFrame': 'At Week 48 (24 weeks after completion of all study interventions at Week 24)', 'description': 'Percentage of participants with HBV DNA \\<LLOQ (20 IU/mL) at Week 48 (that is, 24 weeks after completion of all study interventions at Week 24) without re-starting NA treatment were reported.'}, {'measure': 'Percentage of Participants With Biochemical Flares', 'timeFrame': 'Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'Percentage of participants with biochemical flares were reported. On-treatment biochemical flare was defined as confirmed ALT and/or AST \\>=3\\*ULN and \\>=3\\*nadir, while the participant received any of the study interventions. Off-treatment biochemical flare was defined as confirmed ALT and/or AST =3\\*ULN and =3\\*nadir, while the participants did not receive any of the study interventions (Off treatment, including NA).'}, {'measure': 'Percentage of Participants With Virologic Flares', 'timeFrame': 'Follow-Up Period: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'Percentage of participants with virologic flares were reported. Virologic flare was defined as confirmed HBV DNA \\>peak threshold (lowest peak to qualify as virologic flare was HBV DNA \\>200 IU/mL) in participants who were off-treatment. Off-treatment was defined as the time period after stopping all study treatments (including NA) and had HBV DNA \\<LLOQ (20 IU/mL) at the last observed time point on all study interventions.'}, {'measure': 'Number of Participants Requiring NA Re-treatment', 'timeFrame': 'Follow-Up Period: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4)', 'description': 'Number of participants requiring NA re-treatment based on failure in NA treatment completion criteria (HBsAg \\<10 IU/mL, and HBeAg-negative, and HBV DNA \\< LLOQ (20 IU/mL), and ALT \\<3\\*ULN) were reported.'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax) of JNJ-73763989 (JNJ-73763976 and JNJ-73763924)', 'timeFrame': 'Treatment Period 1: Day 1 Week 1; Treatment Period 2: Day 1, Week 12', 'description': 'The maximum observed plasma concentrations (Cmax) of JNJ-73763989 (JNJ-73763976 and JNJ-73763924) were reported.'}, {'measure': 'Plasma Concentration 24 Hours After Administration (C24h) of JNJ-73763989 (JNJ-73763976 and JNJ-73763924)', 'timeFrame': 'Treatment Period 1: Day 1 Week 1; Treatment Period 2: Day 1, Week 12', 'description': 'Plasma concentration 24 hours (C24h) after administration of JNJ-73763989 (JNJ-73763976 and JNJ-73763924) were reported.'}, {'measure': 'Time to Reach Maximum Observed Plasma Concentration (Tmax) of JNJ-73763989 (JNJ-73763976 and JNJ-73763924)', 'timeFrame': 'Treatment Period 1: Day 1, Week 1; Treatment Period 2: Day 1, Week 12', 'description': 'Time to reach maximum observed plasma concentration (Cmax) (Tmax) of JNJ-73763989 (JNJ-73763976 and JNJ-73763924) were reported.'}, {'measure': 'Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hour (AUC[0-24]h) of JNJ-73763989 (JNJ-73763976 and JNJ-73763924)', 'timeFrame': 'Treatment Period 1: Day 1, Week 1; Treatment Period 2: Day 1, Week 12', 'description': 'Area under the plasma concentration versus time curve from time 0 to 24 hours (AUC\\[0-24\\]h) of JNJ-73763989 (JNJ-73763976 and JNJ-73763924) were reported.'}]}, 'oversightModule': {'isUsExport': True, 'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Hepatitis B, Chronic']}, 'referencesModule': {'references': [{'pmid': '40919077', 'type': 'DERIVED', 'citation': 'Gane E, Janczewska E, Takehara T, Chuang WL, Peng CY, Hlebowicz M, Asahina Y, Chang TT, Kalmeijer R, Jezorwski J, Kim G, Anastasiou Z, Kakuda TN, Verbinnen T, Pehlivanov N, Bakala A, Lenz O, Biermer M. Peginterferon-alpha-2a add-on to treatment with siRNA JNJ-73763989 in virologically suppressed chronic hepatitis B: The phase II PENGUIN study. JHEP Rep. 2025 Jul 9;7(10):101516. doi: 10.1016/j.jhepr.2025.101516. eCollection 2025 Oct.'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to evaluate the efficacy in terms of hepatitis B surface antigen (HBsAg) levels of the study intervention (that is, JNJ-73763989 + JNJ-56136379 + nucleos\\[t\\]ide analog \\[NA\\] and pegylated interferon alpha-2a \\[PegIFN-alpha2a\\]).', 'detailedDescription': 'This study is an intervention specific appendix to the Hepatitis B wings platform trial (PLATFORMPAHPB2001). The study title reflects the original study design and JNJ-56136379 (JNJ-6379) was initially part of the study intervention but has been removed as part of amendment 3 of the study.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '65 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Chronic hepatitis B virus (HBV) infection, hepatitis B e Antigen (HBeAg) positive or negative with suppressed viral replication under nucleos(t)ide analogue treatment for at least 6 months prior to screening\n* Medically stable based on physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at screening\n* Body mass index (BMI) between 18.0 and 35.0 kilogram per meter square (kg/m\\^2), extremes included\n* Must have serum HBsAg greater than (\\>) 100 international units per milliliter (IU/mL) at screening, as assessed by quantitative HBsAg assay\n* Must have a fibroscan stiffness measurement less than or equal to (\\<=) 9.0 Kilopascal (kPa) at screening\n\nExclusion Criteria:\n\n* Evidence of hepatitis A, C, D or E virus infection or human immunodeficiency, virus type 1 (HIV) or HIV-2 infection at screening\n* History or evidence of clinical signs or symptoms of hepatic decompensation, including but not limited to: portal hypertension, ascites, hepatic encephalopathy, esophageal varices\n* Evidence of liver disease of non-HBV etiology\n* Participants with a history of malignancy within 5 years before screening\n* Contraindications to the use of pegylated interferon alpha-2a'}, 'identificationModule': {'nctId': 'NCT04667104', 'acronym': 'PENGUIN', 'briefTitle': 'A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection', 'organization': {'class': 'INDUSTRY', 'fullName': 'Janssen Research & Development, LLC'}, 'officialTitle': 'A Phase 2, Open-label, Single-arm, Multicenter Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Treatment With JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Patients With Chronic Hepatitis B Virus Infection', 'orgStudyIdInfo': {'id': 'CR108928'}, 'secondaryIdInfos': [{'id': '2020-003956-34', 'type': 'EUDRACT_NUMBER'}, {'id': '73763989PAHPB2006', 'type': 'OTHER', 'domain': 'Janssen Research & Development, LLC'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Treatment Period (TP) 1 (JNJ-73763989 + Nucleos(t)ide Analog)+ TP 2 (TP 1+PegIFN-alpha2a)', 'description': 'Participants will receive combination treatment with JNJ-73763989+ nucleos(t)ide analog (NA) for 12 weeks during Treatment Period 1 and the participants who meet the eligibility criteria for PegIFN-alpha2a at Week 12 will receive combination treatment with JNJ-73763989 + NA plus PegIFN-α2a for 12 weeks during Treatment Period 2.', 'interventionNames': ['Drug: JNJ-73763989', 'Drug: Tenofovir disoproxil', 'Drug: Tenofovir alafenamide (TAF)', 'Drug: Entecavir (ETV) monohydrate', 'Drug: PegIFN-alpha2a']}], 'interventions': [{'name': 'JNJ-73763989', 'type': 'DRUG', 'otherNames': ['JNJ-3989'], 'description': 'JNJ-73763989 injection will be administered subcutaneously once every 4 weeks.', 'armGroupLabels': ['Treatment Period (TP) 1 (JNJ-73763989 + Nucleos(t)ide Analog)+ TP 2 (TP 1+PegIFN-alpha2a)']}, {'name': 'Tenofovir disoproxil', 'type': 'DRUG', 'description': 'Tenofovir disoproxil film-coated tablet will be administered orally once daily.', 'armGroupLabels': ['Treatment Period (TP) 1 (JNJ-73763989 + Nucleos(t)ide Analog)+ TP 2 (TP 1+PegIFN-alpha2a)']}, {'name': 'Tenofovir alafenamide (TAF)', 'type': 'DRUG', 'description': 'TAF film-coated tablet will be administered orally once daily.', 'armGroupLabels': ['Treatment Period (TP) 1 (JNJ-73763989 + Nucleos(t)ide Analog)+ TP 2 (TP 1+PegIFN-alpha2a)']}, {'name': 'Entecavir (ETV) monohydrate', 'type': 'DRUG', 'description': 'ETV monohydrate film-coated tablet will be administered orally once daily.', 'armGroupLabels': ['Treatment Period (TP) 1 (JNJ-73763989 + Nucleos(t)ide Analog)+ TP 2 (TP 1+PegIFN-alpha2a)']}, {'name': 'PegIFN-alpha2a', 'type': 'DRUG', 'description': 'PegIFN-alpha2a injection will be administered subcutaneously once weekly.', 'armGroupLabels': ['Treatment Period (TP) 1 (JNJ-73763989 + Nucleos(t)ide Analog)+ TP 2 (TP 1+PegIFN-alpha2a)']}]}, 'contactsLocationsModule': {'locations': [{'zip': '113 8519', 'city': 'Bunkyō City', 'country': 'Japan', 'facility': 'Tokyo Medical and Dental University Hospital', 'geoPoint': {'lat': 35.5331, 'lon': 139.4217}}, {'zip': '565-0871', 'city': 'Suita-shi', 'country': 'Japan', 'facility': 'Osaka University Hospital'}, {'zip': '1010', 'city': 'Auckland', 'country': 'New Zealand', 'facility': 'New Zealand Clinical Research', 'geoPoint': {'lat': -36.84853, 'lon': 174.76349}}, {'zip': '2025', 'city': 'Papatoetoe', 'country': 'New Zealand', 'facility': 'Middlemore Clinical Trials', 'geoPoint': {'lat': -36.9682, 'lon': 174.84019}}, {'zip': '80-462', 'city': 'Gdansk', 'country': 'Poland', 'facility': 'Neutrum Lekarze M.Hlebowicz i Partnerzy spolka partnerska', 'geoPoint': {'lat': 54.35227, 'lon': 18.64912}}, {'zip': '41-400', 'city': 'Mysłowice', 'country': 'Poland', 'facility': 'ID Clinic', 'geoPoint': {'lat': 50.20745, 'lon': 19.16668}}, {'zip': '01-201', 'city': 'Warsaw', 'country': 'Poland', 'facility': 'Wojewodzki Szpital Zakazny w Warszawie', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '50 220', 'city': 'Wroclaw', 'country': 'Poland', 'facility': 'Przychodnia EuroMediCare Wroclaw Lowiecka', 'geoPoint': {'lat': 51.10286, 'lon': 17.03006}}, {'zip': '807', 'city': 'Kaohsiung City', 'country': 'Taiwan', 'facility': 'Kaohsiung Medical University Hospital', 'geoPoint': {'lat': 22.61626, 'lon': 120.31333}}, {'zip': '40447', 'city': 'Taichung', 'country': 'Taiwan', 'facility': 'China Medical University Hospital', 'geoPoint': {'lat': 24.1469, 'lon': 120.6839}}, {'zip': '704', 'city': 'Tainan', 'country': 'Taiwan', 'facility': 'National Cheng Kung University Hospital', 'geoPoint': {'lat': 22.99083, 'lon': 120.21333}}], 'overallOfficials': [{'name': 'Janssen Research & Development, LLC Clinical Trial', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Janssen Research & Development, LLC'}]}, 'ipdSharingStatementModule': {'url': 'https://www.janssen.com/clinical-trials/transparency', 'ipdSharing': 'YES', 'description': 'The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical- trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) project site at yoda.yale.edu'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Janssen Research & Development, LLC', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}